

Table of Contents

About the Editors	v
About the Contributors	ix
Table of Chapters	xxxiii
Table of Contents	xxxvii
About This Book	cxi
Acknowledgments	cxiii
Glossary and Abbreviations	cxv
Current Trends in Health Care M&A	cxlvii
Today's Health Care Legal and Regulatory Environment and Its Impact on the Health Care Marketplace	clxxiii

VOLUME 1

PART I

STRUCTURING HEALTH CARE M&A TRANSACTIONS

Chapter 1 Basic Transaction Structures in Health Care M&A

Andrew L. Bab & Dmitriy A. Tartakovskiy

Acquisition of the Whole Business	1-2
Q 1.1 What is a whole business acquisition?	1-2
Q 1.1.1 What is a stock purchase?	1-3
Q 1.1.2 What is a merger?	1-4
Q 1.1.3 What is a tender offer?	1-5
Q 1.1.4 What is an asset purchase?	1-9
Product and Portfolio Acquisitions	1-10
Q 1.2 What is a product or portfolio acquisition?	1-10
Option Transactions	1-10
Q 1.3 What are typical M&A structures in the pharmaceutical and biotechnology industries?	1-10

Q 1.4	What are the key terms of an option transaction?.....	1-11
Q 1.4.1	What is the purpose of the up-front payment?.....	1-12
Q 1.4.2	What determines the duration of the option?	1-13
Q 1.4.3	How is the option transaction documented?	1-15
Other Structuring Considerations	1-16
Q 1.5	What other factors may affect the structuring decision in health care M&A transactions?	1-16
Q 1.6	When should the transaction be structured as a stock purchase as opposed to an asset purchase?	1-17
Q 1.6.1	What are assumed vs. excluded assets and liabilities?.....	1-17
Q 1.6.2	What are the tax implications of structuring the transaction as a stock or asset deal?.....	1-19
Q 1.6.3	How does the transaction structure affect the need to obtain regulatory approvals and third-party consents?.....	1-22
Q 1.6.4	What are relevant documentary considerations?.....	1-24

Chapter 2 Contingent Payments

Andrew L. Bab

Contingent Value Rights	2-2
Q 2.1	What are contingent value rights?	2-2
Q 2.1.1	What are stock-based CVRs and when are they used?	2-2
Q 2.1.2	What are event-driven CVRs?	2-3
Q 2.2	What events can trigger payments under event-driven CVRs?	2-4
Q 2.3	Are event-driven CVRs equity, debt, or something else entirely?	2-5
Q 2.4	When is an event-driven CVR treated as a security and not a contract right?	2-5
Q 2.5	How are CVRs treated from an accounting perspective?.....	2-6
Q 2.6	Must issuers of CVRs exert a certain level of effort to bring about the agreed milestones?.....	2-7
Q 2.6.1	What efforts obligations may courts imply?.....	2-8
Q 2.6.2	What efforts obligations do health care issuers typically include in their CVR agreements?.....	2-8
Q 2.7	What special issues confront private equity sponsors who buy health care companies and who wish to use CVRs?	2-12

Table of Contents

Earnouts Compared to CVRs	2-13
Q 2.8 What is an earnout?	2-13
Q 2.9 What triggers are used in earnouts?	2-13
Q 2.10 Can earnouts pay the buyer rather than the seller, if the target performs poorly?	2-13
Q 2.11 Do earnouts last as long as CVRs?	2-13
Q 2.12 Are earnouts more likely than CVRs to be enforced?	2-14
Q 2.13 What are the income tax consequences of earnouts?	2-15

Chapter 3 Purchase Price Adjustments

Andrew L. Bab, Dmitriy A. Tartakovskiy & Jonathan L. Lubin

Functions of Purchase Price Adjustments	3-2
Q 3.1 What are the functions of a purchase price adjustment?	3-2
Balance Sheet Adjustments	3-4
Q 3.2 What is the most common type of purchase price adjustment used in health care M&A transactions?	3-4
Q 3.3 What is a working capital adjustment?	3-4
Q 3.3.1 How should working capital be defined in the agreement?	3-5
Q 3.3.2 What is the appropriate baseline for a working capital adjustment?	3-8
Q 3.3.3 What accounting principles should be used in calculating the working capital adjustment?	3-10
Q 3.3.4 What are the mechanics of a working capital adjustment?	3-12
Q 3.4 What other types of balance sheet adjustments are used in health care acquisitions?	3-13
Other Types of Purchase Price Adjustments	3-14
Q 3.5 What other types of purchase price adjustments are used in health care M&A transactions?	3-14
Q 3.5.1 What are event-driven purchase price adjustments?	3-15
Q 3.5.2 What are liability-driven purchase price adjustments?	3-16
Purchase Price Adjustments Versus Indemnification	3-17
Q 3.6 What is the difference between a purchase price adjustment and indemnification?	3-17
Q 3.7 What is the interaction between a working capital adjustment and indemnification provisions?	3-18

Dispute Resolution	3-19
Q 3.8 How are disputes about purchase price adjustments typically resolved?	3-19

Chapter 4 License-and-Collaboration Agreements

Kevin A. Rinker & Henry Lebowitz

Scope of the License	4-2
Q 4.1 What are the principal terms of a license grant for a pharmaceutical product?	4-2
Q 4.1.1 Should a license be exclusive or nonexclusive?.....	4-3
Q 4.1.2 Should the license cover one or more fields of use or should the field of use be unlimited?.....	4-3
Q 4.1.3 Should the license cover one or more jurisdictions or be worldwide?.....	4-4
Payments	4-5
Q 4.2 What are the typical economic arrangements in a license?	4-5
Q 4.2.1 What are up-front payments?	4-5
Q 4.2.2 What are milestone payments?	4-5
Q 4.2.3 What are royalties?	4-6
Q 4.3 Are there other types of payments?.....	4-7
Assigning the Responsibilities of the Parties	4-8
Q 4.4 Which party is typically responsible for development of the product?	4-8
Q 4.5 Which party is typically responsible for filing and maintaining New Drug Applications and conducting related studies?.....	4-8
Q 4.6 Which party is responsible for prosecution of trademarks and patents?.....	4-9
Q 4.7 When should the parties consider a co-promotion arrangement?	4-9
Q 4.8 Should the licensee seek a right of first negotiation, first offer, or first refusal?	4-10
Q 4.9 Should the license-and-collaboration agreement include a noncompetition covenant?	4-10
Q 4.10 Which party is typically responsible for manufacturing?.....	4-11
Q 4.10.1 Should the licensee have manufacturing transfer assistance from the licensor?	4-11
Q 4.11 Under what circumstances may each party terminate the agreement?	4-12

Chapter 5 Joint Ventures and Strategic Alliances

Sarah A.W. Fitts

Objectives	5-2
Q 5.1 Why create a joint venture or strategic alliance in the health care industry?	5-2
Q 5.1.1 Is capital the only reason to consider a joint venture or strategic alliance?	5-3
Q 5.2 What additional motivations might health care service providers have for creating joint ventures and strategic alliances?	5-5
Q 5.3 What additional motivations might pharmaceutical and biotechnology companies have for creating joint ventures and strategic alliances?	5-6
Health Care Providers	5-7
Q 5.4 What are common strategic alliances involving health care service providers?	5-7
Q 5.5 When might a joint venture be appropriate for a hospital or other health care service provider?	5-9
Q 5.6 What else should health care providers keep in mind in determining whether to form a joint venture?	5-11
Pharmaceutical and Biotech Companies	5-12
Q 5.7 What are common joint ventures and strategic alliances involving pharmaceutical and biotechnology companies?	5-12
Q 5.8 What factors influence the structure of the pharmaceutical or biotechnology joint venture or strategic alliance?	5-14
Q 5.8.1 What concerns may influence the allocation of control in pharmaceutical and biotechnology joint ventures and strategic alliances?	5-16
Q 5.9 How should the parties deal with the possibility of termination of the joint venture?	5-17
Examples	5-18
Q 5.10 What are some recent examples of joint ventures in health care services?	5-18
Q 5.11 What are some recent examples of strategic alliances in health care services?	5-20

Q 5.12	What are some recent examples of joint ventures in pharmaceuticals and biotechnology?.....	5-22
Q 5.13	What are some recent examples of strategic alliances in pharmaceuticals and biotechnology?.....	5-24

Chapter 6 Transfer of Regulatory Approvals, Licenses, and Clearances

Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall

Drugs and Biologics	6-2	
Q 6.1	Is it possible to transfer ownership of a New Drug Application or Abbreviated New Drug Application?.....	6-2
Q 6.2	Is it possible to transfer ownership of a Biologics License Application?	6-3
Devices	6-4	
Q 6.3	Is it possible to transfer ownership of a Premarket Approval?	6-4
Q 6.4	Is it possible to transfer ownership of a 510(k)?.....	6-5
Investigational Products	6-7	
Q 6.5	Is it possible to transfer ownership of an IND or IDE?.....	6-7

Chapter 7 Regulatory Issues in Acquisitions of Health Insurers

Nicholas F. Potter, Matthew B. Parelman & Kevin J. Ellis

General Considerations	7-2	
Q 7.1	When does a change of control occur?	7-2
Q 7.2	What are the basic regulatory approvals required in order to effect the acquisition of control of a health insurer?.....	7-2
Q 7.3	If the health insurer is a health maintenance organization, are any additional regulatory approvals required?	7-3
Q 7.4	As a practical matter, what is the best way to manage and coordinate all the jurisdictions where filings are required?	7-5
Form A	7-5	
Q 7.5	What information is required to complete the Form A change-of-control filing?	7-5
Q 7.6	Is information submitted with a Form A confidential?.....	7-7

Table of Contents

Q 7.7	In addition to the insurer's domiciliary regulator, do any other states' insurance regulators have to approve a change of control?	7-8
Form E		7-8
Q 7.8	When is a Form E required?	7-8
Approval Process		7-9
Q 7.9	Once the filings are made, how long will it take to receive an approval?.....	7-9
Additional Approvals and Filings		7-10
Q 7.10	What if the insurer being acquired is a third-party administrator or utilization review agency?	7-10
Q 7.11	If the health insurer being acquired has entered into Medicare or Medicaid contracts, will additional approvals be required?	7-10
Q 7.12	Do federal premerger notification rules apply?.....	7-11
Q 7.13	Are there additional filings that may be required?	7-11

Chapter 8 Not-for-Profit Issues

Michael Bolotin & Lena E. Smith

Public Interest		8-2
Q 8.1	What are the key differences between not-for-profit and for-profit organizations that can affect acquisitions and joint ventures?	8-2
Federal Tax-Exempt Status		8-3
Q 8.2	What are the benefits of tax-exempt status?.....	8-3
Q 8.2.1	If an organization has tax-exempt status, is all of its income exempt from federal tax?.....	8-4
Q 8.3	What are the requirements for tax-exempt status?.....	8-4
Q 8.4	What makes a health care provider's activities "charitable" within the meaning of section 501(c)(3)?.....	8-5
Q 8.4.1	Are additional requirements imposed by the health care reform law?	8-6
Q 8.5	Can a health insurance provider be tax-exempt?.....	8-9
Q 8.6	Can an HMO be tax-exempt?	8-11

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 8.7	Can a tax-exempt, not-for-profit health care provider engage in transactions involving for-profit investors without jeopardizing its exempt status or incurring federal or state sanctions?	8-11
Joint Ventures	8-12
Q 8.8	Why are joint ventures between nonprofit and for-profit entities useful in the health care industry?	8-12
Q 8.9	For the nonprofit to maintain its tax-exempt status, how must the joint venture be structured?	8-12
Q 8.9.1	What sort of control of the joint venture must the nonprofit maintain?	8-13
Q 8.9.2	What other factors are relevant?	8-14
State Law Requirements for Asset Sales	8-15
Q 8.10	What are typical state law requirements for approving a sale of assets by a nonprofit health care organization?	8-15
Q 8.10.1	What are the California requirements?	8-15
Q 8.10.2	What are the Massachusetts requirements?	8-17
Q 8.10.3	What are the New York requirements?	8-18
State Approval of For-Profit's Acquisition of Not-for-Profit Facilities	8-21
Q 8.11	What special conditions can a state impose before granting approval of the acquisition of a nonprofit health care provider's facilities?	8-21
Excess-Benefits Transactions	8-24
Q 8.12	What sanctions can the Internal Revenue Service impose on individuals who receive "excess" benefits in a deal between a nonprofit and a for-profit entity?	8-24
Q 8.13	How does a charitable organization establish the rebuttable presumption that a transaction is not an excess-benefit transaction?	8-25
Q 8.13.1	What is approval by an authorized body?	8-26
Q 8.13.2	What is reliance on comparable data?	8-27
Q 8.13.3	What is the proper-documentation requirement?	8-28

Chapter 9 Antitrust Considerations

Michael Schaper & Matthew J. Petrozziello

Premerger Notification9-2

Q 9.1 What is the Hart-Scott-Rodino Act?9-2

Q 9.2 What types of transactions are covered by the HSR Act?.....9-2

 Q 9.2.1 Are licensing transactions covered by the HSR Act? 9-3

Q 9.3 What information is required in the HSR filing?.....9-4

Q 9.4 What happens after the HSR filing?.....9-4

Q 9.5 What additional information is typically sought by the Assigned Agency during the initial waiting period?9-5

Q 9.6 What happens after the initial waiting period?9-5

 Q 9.6.1 What information is sought by the formal request for additional information (or second request)?9-6

 Q 9.6.2 Once a second request has been issued, is there any possibility of the Agencies granting clearance without substantial compliance?9-6

 Q 9.6.3 How burdensome is compliance with a second request?9-7

Q 9.7 Once the parties submit the information called for by the second request, how does the Assigned Agency proceed?.....9-7

Merger Analysis9-8

Q 9.8 What is merger analysis?.....9-8

Q 9.9 What types of transactions are subject to merger analysis?.....9-8

Q 9.10 How is the relevant product market defined?9-8

 Q 9.10.1 How is the relevant product market defined for hospital mergers?9-9

 Q 9.10.2 How is the relevant product market defined for pharmaceutical mergers?.....9-11

 Q 9.10.3 How is the relevant product market defined for licensing arrangements?.....9-13

Q 9.11 How is the relevant geographic market determined?.....9-16

 Q 9.11.1 How is the relevant geographic market determined for hospital mergers?.....9-16

 Q 9.11.2 How is the relevant geographic market determined for pharmaceutical mergers?.....9-18

Q 9.12 What market conditions are considered in assessing market power?9-20

 Q 9.12.1 How might a merger impair competition in the relevant market?.....9-20

 Q 9.12.2 What types of procompetitive effects might outweigh any potential impairment of competition?9-21

Q 9.13	What other “defenses” might be argued in the face of a post-merger market with competitive impairment?	9-25
Q 9.13.1	What is the “failing firm” defense?	9-25
Q 9.13.2	What is the “ease of entry” defense?	9-27
Protections for Certain Health Care Mergers		9-28
Q 9.14	Does the nonprofit status of a hospital affect the analysis of a merger involving the hospital?	9-28
Q 9.15	What transactions are protected under the state action immunity doctrine?	9-31
Q 9.16	What guidance is available from the antitrust authorities on health care merger analysis?	9-33
Antitrust Considerations Applicable to Patent Pools		9-34
Q 9.17	What are patent pools?	9-34
Q 9.18	What is the Agencies’ approach to reviewing patent pools?	9-34
Q 9.19	What guidance is available from the Agencies on the treatment of patent pools?	9-36

Chapter 10 Valuation Issues

G. Christopher Louis

The Appraisal Process		10-3
Q 10.1	What is an appraisal?	10-3
Q 10.2	Are appraisers and the appraisal process subject to professional standards?	10-3
Q 10.2.1	How do regulatory requirements in the health care industry relate to appraisal standards?	10-3
Q 10.2.2	What is the scope-of-work rule?	10-4
Q 10.2.3	What are the different types of valuation reports?	10-4
Q 10.3	When is a valuation necessary?	10-5
Q 10.4	What is the appropriate standard of value in a given case?	10-6
Q 10.4.1	What is the typical standard of value used in health care transactions?	10-7
Q 10.4.2	What is the typical standard of value used in the pharmaceutical and biotech industry?	10-8
Q 10.5	What are the primary approaches to value?	10-8
Cost Approach		10-9
Q 10.6	What is the cost approach?	10-9
Q 10.7	When is the cost approach most appropriate?	10-9

Table of Contents

Q 10.8	What are the strengths and weaknesses of the cost approach/asset-based approach?	10-10
Q 10.9	How are intangible assets identified and categorized?	10-10
Q 10.9.1	What are market-related intangible assets?.....	10-11
Q 10.9.2	What are consumer-related intangible assets?.....	10-11
Q 10.9.3	What are contract-based intangible assets?	10-12
Q 10.9.4	What are technology-based intangible assets?	10-12
Market Approach		10-12
Q 10.10	What is the market approach?.....	10-12
Q 10.10.1	What is the guideline publicly traded company method?.....	10-13
Q 10.10.2	What is the guideline merged and acquired company method?.....	10-14
Q 10.10.3	What is the direct sales comparison method?	10-15
Q 10.11	When is the market approach most appropriate?	10-15
Income Approach		10-17
Q 10.12	What is the income approach?	10-17
Q 10.13	What is the discounted cash flow analysis?	10-18
Q 10.13.1	What are the main components of a DCF analysis?	10-18
Q 10.13.2	How are revenues estimated?.....	10-19
Q 10.13.3	How are expenses determined?.....	10-19
Q 10.13.4	What is the economic measure generated from the DCF?.....	10-19
Q 10.13.5	What is the reversion?.....	10-20
Q 10.13.6	What are the special considerations in applying the DCF analysis in health care transactions?	10-21
Q 10.14	What are the decision tree method and real options analysis?	10-21
Reconciliation		10-22
Q 10.15	What is the reconciliation?	10-22
Other Functions for Valuation Opinions		10-23
Q 10.16	What is the role of valuation in complying with acquisition accounting rules?	10-23
Q 10.17	How can a valuation be used to facilitate compliance with fraud and abuse laws?	10-24
Q 10.18	How can a valuation opinion be used to ensure compliance with the IRS regulations relating to “excess-benefit transactions”?	10-25

Chapter 11 Financing Drug Development

Robert Masella & Ilir Mujalovic

Background	11-3
Q 11.1 How have companies addressed recent developments in the biopharmaceutical industry?	11-3
Financing from Seed Capital to Initial Public Offering	11-5
Q 11.2 How has the industry financed drug development historically?.....	11-5
Q 11.3 What is the current role of angel investors?	11-5
Q 11.4 What is the current role of venture capital?	11-6
Q 11.5 What is the current role of initial public offerings?	11-6
Post-IPO Financing for Public Biotech Companies	11-8
Q 11.6 What financing needs exist after the initial public offering?	11-8
Q 11.6.1 What is a follow-on offering?.....	11-8
Q 11.6.2 What is a registered direct offering?.....	11-10
Q 11.6.3 What are private investments in public equity?	11-10
Q 11.6.4 What are at-the-market offerings?.....	11-10
Q 11.6.5 What are committed equity financing facilities?	11-11
Q 11.6.6 What other forms of equity financings are used to raise capital?	11-11
Licensing and Other Collaborations Between Pharmaceutical and Biotech Companies	11-11
Q 11.7 Why is licensing becoming more attractive to big pharma?.....	11-11
Q 11.8 What can big pharma and biotech companies each contribute in a collaboration?	11-12
Q 11.9 At what stage of drug development does a collaboration take place?.....	11-12
Q 11.10 What terms can be expected in a licensing transaction?.....	11-13
Q 11.11 When are contingent value rights used?	11-13
More Financing Alternatives	11-13
Q 11.12 What are some alternatives to dilutive equity financing of drug development?	11-13
Q 11.12.1 What is venture lending?.....	11-14
Q 11.12.2 What are royalty-based financings?.....	11-14

Table of Contents

- Q 11.12.3 What are financings linked to clinical research organizations?.....11-15
- Q 11.12.4 What are structured drug development financings?.....11-15

Chapter 12 Financing of Health Care M&A Transactions

Jeffrey E. Ross, Daniel E. Stroik & Brittany Williams

- Acquisition Financing Generally**12-2
- Q 12.1 What are the different types of acquisition financing?.....12-2
 - Q 12.1.1 What is cash-flow financing and how is it used in acquisition financing?.....12-3
 - Q 12.1.2 What is asset-based financing and how is it used in acquisition financing?.....12-4
- Acquisition Financing in the Health Care Industry**12-5
- Q 12.2 What are typical financing concerns when financing the acquisition of a target in the health care industry?.....12-5
- Q 12.3 Why is the “corporate practice of medicine” doctrine relevant to acquisition financing?12-6
- Q 12.4 How does HIPAA affect the due diligence process, inspection rights, enforcement rights, and control mechanisms of a lender?.....12-7
 - Q 12.4.1 Is it possible to avoid having HIPAA apply to a financing?12-9
- Q 12.5 What are typical asset-based financing issues in the health care industry?.....12-9
 - Q 12.5.1 What is a borrowing base?.....12-9
 - Q 12.5.2 What is the typical payor mix in the borrowing base of a borrower in the health care industry?.....12-10
 - Q 12.5.3 What are Medicare and Medicaid?.....12-11
 - Q 12.5.4 How does the payor mix affect collectability of accounts receivable and, in turn, the borrowing base?.....12-11
 - Q 12.5.5 Why do gross and net health care receivable amounts differ substantially?12-13
 - Q 12.5.6 What protections are built into the borrowing base against deterioration of the health care business?.....12-14
 - Q 12.5.7 What issues are associated with lending against inventory in the health care industry?.....12-15

Q 12.6	How predictable is the cash flow of a health care business and how is it relevant for financing?.....	12-15
Q 12.6.1	What are setoff rights?.....	12-16
Q 12.6.2	What is the true-up process?.....	12-17
Q 12.7	How does a lender perfect a security interest in government receivables such as Medicare and Medicaid receivables?.....	12-18
Q 12.7.1	What is Article 9 of the Uniform Commercial Code?.....	12-18
Q 12.7.2	How does Article 9 apply to government receivables?.....	12-18
Q 12.7.3	What are Medicare and Medicaid anti-assignment laws?.....	12-19
Q 12.7.4	How do anti-assignment laws affect acquisition financing in the health care industry?.....	12-20
Q 12.7.5	What is a double lockbox structure?.....	12-22
Q 12.7.6	Does the double lockbox structure provide complete control to the lender?.....	12-22
Q 12.8	What other enforcement risks do lenders face?.....	12-23

Chapter 13 Tax Considerations

Gary M. Friedman

Tax Reform	13-2	
Q 13.1	What are the key provisions of the 2017t tax reform that will affect the pharma industry?.....	13-2
Q 13.2	How does TCJA affect the U.S. federal income tax rate?.....	13-2
Q 13.3	How does TCJA affect U.S. pharma companies with undistributed offshore earnings as of December 31, 2017?.....	13-2
Q 13.4	How does TCJA affect the U.S. regime governing the deferral of foreign income?.....	13-3
Q 13.5	How does TCJA affect U.S. pharma companies that make deductible payments to foreign affiliates?.....	13-4
Tax Consequences of Acquiring Publicly Traded Target Shares for Cash and CVRs	13-6	
<i>Open Transactions</i>	13-6	
Q 13.6	What is the open transaction doctrine?.....	13-6
Q 13.7	Is open transaction reporting available in connection with the issuance of CVRs in a corporate acquisition?.....	13-6
Q 13.8	What is the tax treatment of shareholders who receive CVRs in an open transaction?.....	13-7
Q 13.9	Is the open transaction doctrine always favorable to the taxpayer?.....	13-7

Table of Contents

Closed Transactions.....13-8

Q 13.10 What is the closed transaction doctrine?13-8

Q 13.11 What is the tax treatment of shareholders who receive
CVRs in a closed transaction?13-8

Q 13.12 Can the installment sale method of reporting be used in
connection with the receipt of a CVR?13-9

Other Issues13-9

Q 13.13 What special tax issues may arise when CVRs are issued
to non-U.S. persons?13-9

Q 13.14 Can a CVR that only pays in shares of the issuer be
received free of tax in a corporate reorganization?13-10

Chapter 14 Accounting Considerations

*John M. (Chip) Clark III, John L. Babitt, Peter Hornecker and
Chandan Dargan*

EBITDA14-3

Q 14.1 What is EBITDA and how does it impact valuation?.....14-3

 Q 14.1.1 What are common derivatives of EBITDA?14-4

 Q 14.1.2 What is Management EBITDA?14-6

Q 14.2 What considerations are unique to the health care
industry and result in financial statement risk?.....14-7

Revenue Recognition14-8

Q 14.3 What are the primary considerations with respect to
proper revenue recognition?14-8

Q 14.4 What are the gross-to-net revenue reconciling items
impacting revenue recognition in health care services
companies?14-12

Q 14.5 What are the gross-to-net-revenue adjustments impacting
revenue recognition in life sciences companies?14-14

 Q 14.5.1 How are product returns handled?.....14-15

 Q 14.5.2 How are chargebacks handled?14-15

Q 14.6 What is the potential impact of the new revenue recognition
standard on life sciences transactions?14-16

 Q 14.6.1 What is the potential impact on collaboration
arrangements?14-17

 Q 14.6.2 What is the potential impact on estimating variable
consideration?14-18

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 14.6.3	What is the potential impact on reseller and distributor arrangements?	14-20
Q 14.6.4	What is the potential impact on licenses of intellectual property?	14-20
Q 14.7	What are the general revenue recognition considerations related to research and development arrangements between life sciences entities?	14-22
Q 14.8	How can one determine the substance of a R&D arrangement?	14-23
Q 14.9	What are the accounting considerations for R&D arrangements from the point of view of the entities involved?	14-27
Q 14.10	How are collaborations or arrangements to perform R&D services that are not financing arrangements accounted for?	14-29
Q 14.11	How should up-front fees be recognized for R&D activity?	14-32
Q 14.12	What are common considerations for contracts with multiple performance obligations?	14-32
Q 14.13	What are important revenue recognition issues related to intellectual property licensing?	14-34
Balance Sheet Considerations	14-35
Q 14.14	What balance sheet considerations are particularly important during due diligence?	14-35
Q 14.15	What is unique about patient receivables in a health care services setting?	14-35
Q 14.16	How will the new credit impairment standard affect a target company's periodic assessment of credit losses for most financial assets that may impact the expected margin and equity?	14-36
Q 14.17	What are third-party settlements?	14-37
Q 14.18	What are medical claims liabilities?	14-38
Q 14.19	What risks arise in analyzing medical malpractice, workers' compensation, and other self-insured claims?	14-38
Q 14.20	What are key considerations with respect to product warranties with life sciences companies?	14-39
Q 14.21	How should R&D costs be treated in financial statements?	14-40
Q 14.22	What other liabilities should be considered in conducting due diligence of health care entities?	14-42
Q 14.23	What are restructuring reserves and expenses?	14-42

Table of Contents

Commitments and Contingencies	14-43
Q 14.24 What are commitments and contingencies?.....	14-43
Q 14.24.1 How are commitments and contingencies quantified?	14-44
Q 14.25 What types of commitments and contingencies are common in health care services entities?	14-45
Q 14.25.1 What risks relate to managed care agreements with employers or subcontract agreements with payors?.....	14-45
Q 14.25.2 What risks relate to physician guarantees?.....	14-45
Change in Control	14-46
Q 14.26 What change-in-control considerations are there with respect to share-based compensation?.....	14-46
Q 14.27 What change-in-control considerations are there with respect to employment contracts?	14-47
Q 14.28 What change-in-control considerations are raised by debt and financing agreements?.....	14-48
Q 14.29 What change-in-control considerations are specific to joint ventures and alliances?	14-48
Q 14.30 What change-in-control considerations are raised by licenses and service contracts?	14-48
Risk-Based Capital	14-48
Q 14.31 What is risk-based capital?	14-48
Q 14.32 What is statutory net worth?.....	14-49
Q 14.33 How does SAP accounting impact statutory net worth?.....	14-49
Q 14.34 What calculations are typically used to assess the adequacy of an insurer's statutory net worth?	14-50
Q 14.34.1 What measure do most advisors use to assess an insurer's statutory net worth?.....	14-50
Q 14.35 How are the insurer's RBC ratio and authorized control level calculated?	14-51
Q 14.36 Why are RBC and statutory net worth relevant in health care M&A?	14-51
Financial Statements Needed to Finance and Complete an Acquisition	14-52
Q 14.37 What are the SEC reporting requirements for public companies in connection with acquisitions?.....	14-52
Q 14.38 What tests are used to determine whether an acquisition is considered to be a significant subsidiary?.....	14-53
Q 14.39 What are the timing requirements for filing?	14-54

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 14.40	What are the requirements with respect to foreign acquisitions?	14-55
Q 14.41	What is pro forma financial information as required by the SEC?	14-56
Q 14.42	For what period is pro forma financial information required?.....	14-57
Q 14.43	What are pro forma adjustments?.....	14-58
Q 14.43.1	When are pro forma adjustments factually supportable?	14-59
Q 14.43.2	How are purchase price allocations handled?	14-60
Q 14.43.3	What new arrangements should be presented as pro forma adjustments?	14-62
Q 14.43.4	What adjustments are inappropriate in pro forma financial statements?	14-62
Q 14.44	What financial statements do banks require in connection with an acquisition?	14-63
Q 14.45	What are the recent SEC proposals changing disclosure requirements for acquisitions and disposal of businesses?	14-64
Q 14.45.1	What is proposed regarding the significance tests?	14-64
Q 14.45.2	What is proposed regarding use of abbreviated financial statements?	14-65
Q 14.45.3	What is proposed regarding the number of audited and interim periods?.....	14-65
Q 14.45.4	What is proposed regarding pro forma financial information?.....	14-66
Q 14.45.5	What other changes are proposed?.....	14-66
Other Bank Requirements		14-66
Q 14.46	What should I consider in negotiating bank covenants?	14-66
Q 14.47	What are reasonable financial reporting requirements?.....	14-68
Q 14.48	What is minimum working capital?	14-68
Acquisition Method		14-69
Q 14.49	Under what circumstances does the acquisition method of accounting apply?	14-69
Q 14.50	How does the acquirer determine whether or not a transaction is considered a business combination?.....	14-70
Q 14.51	What are the accounting considerations in assessing the valuation of the balance sheet?.....	14-72
Q 14.52	What is pushdown accounting?.....	14-72
Q 14.53	When can pushdown accounting be applied?.....	14-73

Table of Contents

Q 14.54	What are the most important measurement and recognition concepts and what are the exceptions?	14-73
Q 14.55	How does the acquisition method of accounting impact inventory?	14-74
Q 14.56	What are considerations in a business combination when an acquirer has a preexisting relationship with the target?	14-75
Q 14.57	How does the acquisition method of accounting impact leases?.....	14-75
Q 14.58	How does the acquisition method of accounting impact research and development assets?.....	14-76
Q 14.59	What is the subsequent accounting for IPR&D acquired in a business combination?.....	14-76
Q 14.60	What should an acquirer consider in evaluating a target company's deferred revenue?.....	14-77
Earnouts	14-79
Q 14.61	When are earnouts used in acquisitions and what are the accounting implications?	14-79

**PART II
DUE DILIGENCE**

**Chapter 15 Introduction to Due Diligence in Health Care
M&A Transactions**

*Andrew L. Bab, Dmitriy A. Tartakovskiy &
Jonathan L. Lubin*

Due Diligence Generally	15-3
Q 15.1	Why is due diligence important?.....	15-3
Q 15.2	When is due diligence conducted?	15-4
Due Diligence in Health Care Deals	15-5
Q 15.3	What is the proper scope of health care M&A due diligence?.....	15-5
Q 15.4	What are the key areas of health care M&A due diligence?.....	15-7
Q 15.5	Who are the key parties and how are due diligence responsibilities typically allocated?	15-7

Chapter 16 Product Development and Marketing

Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall

Definitions	16-2
Q 16.1 What is a “drug” under the Federal Food, Drug, and Cosmetic Act?	16-2
Q 16.2 What is a “new drug”?.....	16-3
Q 16.3 What is a “biologic”?	16-4
Q 16.4 What is a “medical device”?.....	16-4
Q 16.4.1 Is software considered a medical device?.....	16-5
Q 16.4.2 What is a “combination product”?	16-6
Q 16.5 What categories of medical devices are regulated by FDA?	16-7
Q 16.5.1 What is a Class I medical device?.....	16-10
Q 16.5.2 What is a Class II medical device?.....	16-11
Q 16.5.3 What is a Class III medical device?.....	16-11
Q 16.5.4 What is an Emergency Use Authorization (EUA)?.....	16-11
Preclinical Testing	16-12
Q 16.6 What is preclinical testing and why is it conducted?	16-12
Q 16.7 What types of preclinical tests must be completed before engaging in clinical testing in humans?.....	16-12
Q 16.8 What are good laboratory practices for preclinical testing?	16-13
Clinical Studies: The IND and IDE Processes	16-15
Q 16.9 What are clinical studies?	16-15
Q 16.10 What are the clinical trial registry requirements?	16-16
Q 16.11 What is the Investigational New Drug process?	16-16
Q 16.11.1 What is a “sponsor” of an IND?.....	16-17
Q 16.11.2 What are an IND sponsor’s responsibilities?	16-17
Q 16.12 What is an Investigational Device Exemption?	16-19
Q 16.13 What device studies do not require an IDE?	16-20
Q 16.14 What device studies require an IDE?	16-21
Q 16.14.1 What is the procedure for investigational devices that present nonsignificant risks?	16-21
Q 16.14.2 What is the procedure for investigational devices that present significant risks?.....	16-21
Q 16.15 What phases of clinical studies are conducted during the IND process?.....	16-22
Q 16.16 What is an institutional review board (IRB)?.....	16-24

Table of Contents

Clinical Studies: Good Clinical Practice Requirements	16-25
Q 16.17 What are FDA's good clinical practice (GCP) requirements?.....	16-25
Q 16.18 What are the requirements for obtaining informed consent from study subjects?.....	16-26
Q 16.18.1 What information must be provided to subjects?	16-26
Q 16.18.2 Are there exceptions to the informed consent requirements?.....	16-28
Q 16.19 What financial disclosures must be made by clinical investigators?.....	16-29
Q 16.19.1 What must be included in FDA Form 3455?	16-30
Q 16.19.2 What must be included in FDA Form 3454?	16-30
Q 16.19.3 What can FDA do if it has concerns about an investigator's financial bias?.....	16-31
Other FDA Powers	16-31
Q 16.20 With regard to clinical studies, what inspection rights does FDA have?.....	16-31
Q 16.21 What is an FDA clinical hold?	16-32
Applications to FDA	16-32
Q 16.22 What is a New Drug Application?	16-32
Q 16.23 What is an Abbreviated New Drug Application?	16-33
Q 16.24 What is a 505(b)(2) NDA?	16-33
Q 16.25 What is a biologics license application (BLA)?.....	16-34
Q 16.26 Is there an approval process for generic or "follow-on" biologics?.....	16-35
Q 16.27 What is a device premarket approval application?.....	16-35
Q 16.28 What is a device 510(k) clearance?.....	16-36
Q 16.28.1 What is an abbreviated 510(k)?	16-37
Q 16.28.2 What is a special 510(k)?.....	16-37
Q 16.29 What is a De Novo classification request?	16-38
Q 16.30 Can any medical devices be marketed without prior FDA review or approval?	16-39
Application Fees	16-39
Q 16.31 What diligence is needed regarding payment of application fees to FDA?.....	16-39

Q 16.32	What are drug user fee laws?	16-39
Q 16.32.1	Can companies obtain a waiver of PDUFA user fees?	16-41
Q 16.32.2	Can “small” companies obtain a waiver of PDUFA user fees?	16-41
Q 16.33	What is the Medical Device User Fee and Modernization Act?	16-42
Q 16.33.1	Can companies obtain a waiver of MDUFMA user fees?	16-43
Q 16.34	What is the Biosimilar User Fee Act?	16-43
Assessing the Target’s Regulatory Basis for Marketing Regulated Products		
Q 16.35	What are basic diligence issues regarding the target’s marketing of drug, biologic, and medical device products?	16-44
Q 16.36	What is FDA’s over-the-counter drug review process?	16-45
Q 16.37	What if the target produces homeopathic drugs?	16-48
Q 16.38	What issues are raised by unapproved drugs?	16-49
Q 16.39	What issues are raised by 510(k) clearances?	16-51
Q 16.40	What issues are raised by medical devices marketed without prior FDA review or approval?	16-52
Q 16.41	What issues are raised by modifications to a drug, device, or biologic that has been approved or cleared by FDA?	16-53
Q 16.42	What issues are raised by promotion of drugs limited to certain indications?	16-54
Q 16.43	What issues are raised by drug approval limited to specific patient populations?	16-54
Q 16.44	What other limitations may be placed on a product by the terms of its approval or clearance?	16-55
Patient Access to Investigational Products		
Q 16.45	What is FDA’s expanded access program?	16-56
Q 16.46	How does the Right to Try Act affect patient access?	16-56
Postapproval Requirements		
Q 16.47	What are postapproval requirements for approved or cleared products?	16-57
Q 16.48	What types of postapproval requirements can FDA impose on drug products?	16-58
Q 16.48.1	What NDA and ANDA supplements may be required?	16-58
Q 16.48.2	What annual reports may be required?	16-59
Q 16.48.3	What postmarket studies may be required?	16-59

Table of Contents

Q 16.49	What types of postapproval requirements can FDA impose on medical devices?	16-61
Q 16.49.1	What PMA supplements may be required?	16-61
Q 16.49.2	What annual reports may be required?	16-61
Q 16.49.3	What postmarket studies may be required?	16-62
Q 16.49.4	What general postapproval requirements may be imposed?	16-62

Chapter 17 Patent Extensions and Market Exclusivities

Paul D. Rubin, Melissa B. Runsten & Carey B. Nuttall

Summary of Incentives	17-2	
Q 17.1	What are the chief ways in which the law creates incentives for drug development and competition?	17-2
Extensions of Patent Term	17-6	
Q 17.2	What are the available statutory patent term extensions?	17-6
Exclusivities	17-7	
Q 17.3	What is five-year “new chemical entity” exclusivity under the Hatch-Waxman Act?	17-7
Q 17.4	What is three-year exclusivity under the Hatch-Waxman Act?	17-8
Q 17.5	What is seven-year orphan drug exclusivity?	17-8
Q 17.6	What is six-month pediatric exclusivity?	17-9
Q 17.7	What is five-year Qualified Infectious Disease Product (QIDP) exclusivity?	17-9
Q 17.8	What is innovator product exclusivity for biologic products?	17-10
Q 17.9	What are 180-day generic drug exclusivity, follow-on biologic exclusivity, and the thirty-month stay of generic drug approval?	17-11
Q 17.10	What is competitive generic therapy exclusivity?	17-12
Q 17.11	What is eighteen-month OTC drug exclusivity?	17-12

Chapter 18 Manufacturing and Distribution Requirements

Paul D. Rubin, Melissa B. Runsten, Adriana D. Kohler & Anne D. Spiggle

Good Manufacturing Practices	18-2
Q 18.1 What are FDA’s good manufacturing practice requirements for drugs?	18-2
Q 18.2 What are FDA’s quality system regulations?	18-3
Q 18.3 Can FDA inspect the premises of drug, biologic, and device manufacturers?.....	18-3
Q 18.4 What due diligence is appropriate regarding current good manufacturing practices?.....	18-4
Standard Operating Procedures	18-5
Q 18.5 What are “standard operating procedures” for drug, device, and biologic operations?	18-5
Q 18.6 What types of operations should be supported by written SOPs?	18-5
Q 18.7 What are the benefits of maintaining standard operating procedures?.....	18-5
Q 18.8 What due diligence should be conducted regarding the target’s standard operating procedures?	18-6
Systems for Handling Reports of Failures or Malfunctions	18-6
Q 18.9 What systems should a company have for responding to product failures or malfunctions?	18-6
Q 18.10 What are “corrective and preventive action” requirements generally?	18-7
Q 18.11 What are the CAPA requirements for medical devices?	18-7
Q 18.12 What are the CAPA requirements for drugs and biologics?.....	18-8
Q 18.13 What due diligence should be conducted regarding the target’s CAPA systems?.....	18-9
Contract Manufacturers	18-10
Q 18.14 What role do contract manufacturers play in the industry?	18-10
Q 18.15 What are the respective responsibilities of contract manufacturers and entities holding FDA approvals or clearances?.....	18-11
Q 18.16 What due diligence should be conducted regarding the target’s use of contract manufacturers?.....	18-12

Table of Contents

Establishment Registration, Product Listing, and Requirements for Bulk Active Pharmaceutical Ingredients	18-12
Q 18.17 What are FDA registration requirements for drug and device establishments?.....	18-12
Q 18.18 What due diligence should be conducted regarding registration issues?	18-13
Q 18.19 What are FDA listing requirements for drugs and devices?.....	18-13
Q 18.20 What due diligence should be conducted regarding listing issues?.....	18-14
Q 18.21 What are the requirements for bulk active pharmaceutical ingredients?.....	18-14
Q 18.22 What due diligence should be conducted regarding bulk active pharmaceutical ingredients?.....	18-15
Distribution of Prescription Drugs	18-15
Q 18.23 What is the closed drug distribution system?.....	18-15
Q 18.24 What is the Drug Supply Chain Security Act?.....	18-15
Q 18.25 What is the Prescription Drug Marketing Act?.....	18-16
Q 18.26 What are licensed drug distributors?.....	18-16
State Licensing Requirements	18-17
Q 18.27 Do the states require licenses to manufacture, repackage, or distribute drugs, biologics, or medical devices?	18-17
Q 18.28 What due diligence should be conducted regarding the target's state law licensing?	18-17

Chapter 19 FDA Investigations and Enforcement

Paul D. Rubin, Melissa B. Runsten, Anne D. Spiggle & Alexandra S. Marzelli

Inspections	19-2
Q 19.1 What is an FDA inspection?.....	19-2
Q 19.2 What is FDA Form 483?.....	19-2
Q 19.2.1 Must a company respond to a Form 483?	19-3
Q 19.2.2 What is the significance of Form 483 for due diligence?.....	19-3
Q 19.3 How does FDA classify inspection results?.....	19-4
Q 19.4 What is an establishment inspection report?.....	19-4

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 19.5	Where can official information about past inspections be found?	19-5
Q 19.6	What other inspection-related communications with FDA are relevant to due diligence?.....	19-5
Enforcement Mechanisms		19-6
Q 19.7	What is FDA's general enforcement authority?	19-6
Q 19.8	What is a warning letter?.....	19-7
Q 19.9	What is an untitled letter?	19-7
Q 19.10	What is a seizure?.....	19-8
Q 19.11	What is an injunction?	19-8
Q 19.12	What is an FDA consent decree?	19-9
Q 19.13	What criminal penalties are available under the FFDCFA?	19-9
Q 19.14	What civil monetary penalties are available under the FFDCFA?	19-10
Q 19.15	What are disqualification and debarment?	19-10
Q 19.16	What are due diligence considerations regarding corrective actions in response to FDA enforcement?.....	19-11
Product Recalls and Market Withdrawals		19-11
Q 19.17	What are product recalls?	19-11
Q 19.18	How does FDA classify recalls?	19-12
Q 19.19	What are "voluntary" recalls?.....	19-13
Q 19.19.1	What are FDA-requested recalls?	19-13
Q 19.19.2	What information must be provided to FDA if a company initiates a recall?	19-13
Q 19.20	When can FDA recall medical devices?	19-14
Q 19.21	When can FDA recall biological products?	19-15
Q 19.22	What is a market withdrawal?	19-15
Q 19.23	What is a stock recovery?	19-15
Reporting Adverse Events		19-16
Q 19.24	What is an adverse drug event?	19-16
Q 19.25	How does a company find out about adverse events involving its drugs?	19-16
Q 19.26	What is an adverse event report?	19-16
Q 19.27	Is adverse event reporting required for nonprescription, over-the-counter drugs?	19-17
Q 19.28	Is adverse event reporting required for medical devices?.....	19-18
Q 19.28.1	What MDR event reports must be made by user facilities?.....	19-18

Table of Contents

Q 19.28.2	What MDR event reports must be made by manufacturers?.....	19-19
Q 19.29	What systems should a company have for responding to and reporting adverse drug events?.....	19-19
Q 19.30	What systems should a company have for responding to and reporting adverse medical device events?	19-20

Chapter 20 Promotion and Advertising

Carey B. Nuttall

General Principles	20-2	
Q 20.1	What are the fundamental requirements for drug promotion and advertising?	20-2
Q 20.2	How do FDA and FTC share regulation of drug advertising?.....	20-2
FDA Regulation of Drug Promotion and Advertising	20-3	
Q 20.3	What are advertising and promotional labeling?	20-3
Q 20.4	What is “off-label” promotion?.....	20-3
Q 20.5	What is risk information and how is it to be disclosed?	20-4
Q 20.6	What else can cause drug promotion to be considered misleading?.....	20-6
Q 20.7	What are the rules for direct-to-consumer advertising?	20-7
Q 20.8	What is drug preapproval promotion?	20-7
Q 20.9	Must promotional materials be submitted to or approved by FDA?	20-8
Q 20.10	What is the Office of Prescription Drug Promotion?	20-8
FDA Regulation of Device Marketing and Advertising	20-9	
Q 20.11	How does FDA regulate device marketing and advertising?.....	20-9
FTC Advertising Requirements	20-10	
Q 20.12	How do the FTC and FDA work together to regulate drug and device promotion?.....	20-10
Q 20.13	What are the basic principles of FTC advertising regulation?.....	20-10

Chapter 21 Compliance with Import and Export Requirements

Paul D. Rubin, Melissa B. Runsten & Eric T. Rasmussen

FDA Import Regulation	21-2
Q 21.1 What is FDA's general authority over imports?.....	21-2
Q 21.2 How is responsibility for imports shared by FDA and Customs and Border Protection?.....	21-2
Q 21.3 How does FDA become aware of an import subject to its authority?.....	21-2
Q 21.4 What initial steps does FDA take to determine if an imported article violates the law?.....	21-3
Q 21.5 What is the procedure when no violation is found?.....	21-3
Q 21.6 What is the procedure when a violation is found?.....	21-3
Q 21.7 What if the imported article is intended for export from the United States?.....	21-5
Q 21.8 What is FDA's authority to refuse imports under the "appears-to-be-violative" standard?.....	21-5
Q 21.9 What are FDA import alerts?.....	21-6
Q 21.10 How does FDA regulate the importing of active pharmaceutical ingredients?.....	21-7
FDA Export Regulation	21-7
Q 21.11 What are FDA requirements to export a product produced in compliance with the FFDCRA?.....	21-7
Q 21.12 Can adulterated or misbranded products be exported?.....	21-8
Q 21.12.1 How can a company establish that a product meets the specifications of a foreign purchaser?.....	21-8
Q 21.12.2 How can a company establish that a product does not conflict with the laws of the importing country?.....	21-9
Q 21.12.3 How can a company satisfy the labeling requirement?.....	21-10
Q 21.12.4 How can a company show that the product is not sold or offered for sale in the United States?.....	21-10
Q 21.13 Can unapproved drugs, biological products, and devices be exported?.....	21-11
Q 21.13.1 What are the basic export requirements for unapproved drugs, biological products, and devices?.....	21-12

Table of Contents

Q 21.13.2	What are the additional requirements to export unapproved drugs, biological products, and devices to a listed country?	21-13
Q 21.13.3	What are the additional requirements to export unapproved new drugs, biological products, and devices, to an unlisted country?	21-15

Chapter 22 Miscellaneous Communications with FDA

Paul D. Rubin, Melissa B. Runsten, & Anne D. Spiggle

Comments and Petitions	22-2	
Q 22.1	When does FDA solicit comments regarding rulemakings, guidance documents, or other topics?.....	22-2
Q 22.2	What is a Citizen Petition to FDA?.....	22-2
Q 22.3	How is FDA addressing misuse of Citizen Petitions?	22-3
Other Communications	22-4	
Q 22.4	What other formal or informal communications with FDA should be investigated?.....	22-4

Chapter 23 Compliance with DEA Controlled Substance Requirements

Paul D. Rubin, Melissa B. Runsten & Eric T. Rasmussen

Scheduled Drugs	23-2	
Q 23.1	What are the general consequences of scheduling a drug as a controlled substance?.....	23-2
Q 23.2	What are the five schedules of controlled substances?	23-3
Q 23.3	What is the process by which drug substances are scheduled?.....	23-3
Registration	23-4	
Q 23.4	Who must register with the DEA?	23-4
Quotas	23-5	
Q 23.5	What are DEA's manufacturing and procurement quotas for controlled substances?.....	23-5

Security	23-5
Q 23.6 What are the general requirements for security in storing and handling controlled substances?.....	23-5
Q 23.7 What factors does DEA consider in evaluating whether a company has good security regarding controlled substances?.....	23-6
Q 23.8 What are the storage requirements for controlled substances?.....	23-7
Q 23.9 How are manufacturing processes regulated?.....	23-7
Q 23.10 What are the security requirements for distribution and shipping?.....	23-8
Recordkeeping and Reporting	23-8
Q 23.11 What records must be kept by those working with controlled substances?.....	23-8
Q 23.12 What reporting obligations do registrants have?.....	23-9
Inspections and Enforcement Actions	23-9
Q 23.13 What are DEA’s inspection powers?.....	23-9
Q 23.14 When does DEA need a warrant to make an inspection?.....	23-10
Q 23.15 How often do inspections occur?.....	23-11
Q 23.16 What administrative enforcement actions can the DEA pursue?.....	23-11
Q 23.17 Can the DEA seek monetary penalties?.....	23-12
Q 23.18 Can the DEA seek criminal penalties?.....	23-12
Q 23.19 Has the DEA pursued enforcement actions targeted at the ongoing opioid crisis?.....	23-12

Chapter 24 Compliance with Federal and State Health Care Fraud and Abuse Laws

John S. (Jay) Darden

The Anti-Kickback Statute	24-3
Q 24.1 What is the Anti-Kickback Statute?.....	24-3
Q 24.2 What kinds of payment are prohibited?.....	24-3
Q 24.3 What level of knowledge and intent is required?.....	24-5
Q 24.4 To whom does the Anti-Kickback Statute apply?.....	24-5
Q 24.5 To what types of goods and services does the Anti-Kickback Statute apply?.....	24-5

Table of Contents

Q 24.6	What is a “federal health care program”?	24-6
Q 24.7	Are there any statutory safe harbors?	24-6
Q 24.8	Are there any regulatory safe harbors?	24-7
Q 24.9	What criteria must be satisfied for a payment to fall within a safe harbor?	24-9
Q 24.10	What are the potential direct consequences of an anti-kickback violation?	24-10
Q 24.11	What are the potential collateral consequences of an anti-kickback violation?	24-10
Q 24.12	What due diligence is appropriate regarding anti-kickback issues?	24-11
The Stark Law		24-13
Q 24.13	What is the Stark law?	24-13
Q 24.14	What intent is required for a violation of the Stark law?	24-14
Q 24.15	What are the differences between the Stark law and the Anti-Kickback Statute?	24-15
Q 24.16	To what services does the Stark law apply?	24-16
Q 24.17	What is a “referral” for purposes of the Stark law?	24-17
Q 24.18	Are there any exceptions to the Stark law?	24-17
Q 24.18.1	What is the hospital-ownership exception?	24-18
Q 24.18.2	What is the personal-services exception?	24-18
Q 24.19	What are the potential direct consequences of a Stark law violation?	24-19
Q 24.20	What are the potential collateral consequences of a Stark law violation?	24-20
Q 24.21	What due diligence is appropriate regarding Stark law issues?	24-20
The False Claims Act		24-21
Q 24.22	What is the False Claims Act?	24-21
Q 24.23	What is a “claim”?	24-22
Q 24.24	What are “false or fraudulent” claims?	24-22
Q 24.25	What level of knowledge or intent is required?	24-22
Q 24.26	Who is liable for the submission of false or fraudulent claims?	24-23
Q 24.27	What are the potential consequences of a False Claims Act violation?	24-23
Q 24.28	What are the qui tam provisions?	24-24
Q 24.28.1	What is the relator’s share?	24-24

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 24.29	What changes to the False Claims Act were made by PPACA?.....	24-25
Q 24.30	Are there state false claims statutes?.....	24-25
Q 24.31	What due diligence is appropriate regarding False Claims Act issues?.....	24-25
Criminal Offenses		24-27
Q 24.32	What is criminal “health care fraud”?.....	24-27
Q 24.33	To what services does the health care fraud statute apply?.....	24-27
Q 24.34	What is a “health care benefit program”?.....	24-27
Q 24.35	How does the fraud statute differ from the Anti-Kickback Statute and Stark law?.....	24-28
Q 24.36	To whom does the health care fraud statute apply?.....	24-28
Q 24.37	What is a criminal conspiracy, and why might conspiracy charges be useful to prosecutors in health care fraud cases?.....	24-29
Q 24.38	What level of knowledge and intent is required for a violation of the health care fraud statute?.....	24-29
Q 24.39	Is the fraud victim’s lack of care a defense?.....	24-30
Q 24.40	What are the potential direct consequences of a health care fraud violation?.....	24-30
Q 24.41	What are the potential collateral consequences of a health care fraud violation?.....	24-31
Q 24.42	What due diligence is appropriate regarding criminal health care fraud issues?.....	24-32
State Criminal Health Care Fraud and Abuse Statutes		24-32
Q 24.43	Are there state criminal health care fraud and abuse statutes?.....	24-32
Q 24.44	What are state “corporate practice of medicine” laws?.....	24-32
Q 24.45	What are the potential consequences for a violation of corporate practice of medicine laws?.....	24-33
Compliance Programs		24-34
Q 24.46	What is a compliance program and why is it important?.....	24-34
Q 24.47	What are the duties of a chief compliance officer?.....	24-34
Q 24.48	What should you expect to see in a compliance program?.....	24-35
Q 24.49	How should a compliance program be structured?.....	24-35
Q 24.50	What is the relevance of the U.S. Sentencing Guidelines to compliance programs?.....	24-36

Table of Contents

Q 24.51	What other guidance is available from the government?	24-37
Q 24.52	What is a corporate integrity agreement?.....	24-37
Q 24.53	What due diligence is appropriate for the target's compliance program?	24-38

Chapter 25 Regulatory Issues in Acquisitions of Health Care Facilities and Physician Practices

Stephen P. Nash & Michi M. Tsuda

Acquisitions of Licensed Health Care Facilities	25-2	
Q 25.1	What are the principal health care regulatory issues likely to be implicated in the acquisition of a hospital or other type of licensed health care facility?.....	25-2
Q 25.2	What state health care regulations may impact the acquisition of a licensed health care facility?.....	25-4
<i>Transfer of the License.....</i>	<i>25-5</i>	
Q 25.3	What is a health care facility license?.....	25-5
Q 25.4	How may the benefit of a health care facility license be “transferred” from seller to buyer?.....	25-5
Q 25.5	Does a “change in control” of a licensed health care facility require prior notice and also approval?.....	25-7
Q 25.6	Are there similar requirements for the Medicare and Medicaid programs?.....	25-8
<i>Transfer of the Certificate of Need.....</i>	<i>25-10</i>	
Q 25.7	What is a certificate of need program?.....	25-10
Q 25.8	How is the benefit of a certificate of need “transferred” from seller to buyer?.....	25-10
Q 25.9	Is prior notice or approval required?	25-11
<i>Other Permits and Approvals.....</i>	<i>25-12</i>	
Q 25.10	What other health care–related permits may require attention?.....	25-12
Q 25.11	When might the host state’s attorney general become involved?.....	25-13
<i>Medicare and Other Federal Law Issues</i>	<i>25-14</i>	
Q 25.12	What are the sources of federal health care regulation that may impact the acquisition of a licensed health care facility?	25-14

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 25.13	What Medicare regulations and rules may be implicated in an acquisition?	25-15
Q 25.14	What are Provider Transaction Access Numbers and National Provider Identification Numbers?	25-15
Q 25.15	What are Medicare “conditions of participation” and “conditions for coverage”?	25-16
Q 25.16	What approvals are required for a licensed health care facility to provide and bill for services to Medicare beneficiaries?	25-17
Q 25.17	How does the buyer secure the right for the acquired facility to continue to provide and bill for services to Medicare beneficiaries?	25-18
Q 25.18	What is a Medicare CHOW?	25-19
Q 25.19	How may the buyer handle regulatory risks arising from the seller’s pre-acquisition operation of the health care facility?	25-22
	<i>Other Federal Approvals</i>	25-24
Q 25.20	What approvals are required for a clinical laboratory?	25-24
Q 25.21	What approvals are required for a pharmacy?	25-25
Q 25.22	What are the requirements for accreditation and why do they matter?	25-26
	Acquisitions of Physician Practices	25-27
Q 25.23	What areas of state health care regulation may impact the acquisition of a physician practice?	25-27
	<i>Corporate Practice of Medicine</i>	25-27
Q 25.24	What is the corporate practice of medicine?	25-27
Q 25.25	What is the underlying public policy?	25-28
Q 25.26	Are there exceptions to CPOM prohibitions?	25-28
Q 25.27	How do CPOM considerations affect the transaction structure?	25-28
	<i>Fee-Splitting</i>	25-29
Q 25.28	What is fee-splitting?	25-29
Q 25.29	What is the public policy underlying the prohibitions?	25-29
Q 25.30	Are there exceptions to fee-splitting prohibitions?	25-30
Q 25.31	How do fee-splitting considerations affect the transaction structure?	25-30

Table of Contents

<i>Covenants Not to Compete</i>	25-31
Q 25.32 What is a covenant not to compete?	25-31
Q 25.33 What is the public policy underlying the limitations?.....	25-32
Q 25.34 In what situations is a covenant not to compete most likely to be enforceable?.....	25-32
Q 25.35 How do limitations on the use of covenants not to compete affect the transaction structure?.....	25-33
<i>Patient Records</i>	25-34
Q 25.36 What limitations arise in connection with the transfer and maintenance of patient medical records?.....	25-34
<i>Medicare and Other Federal Law Issues</i>	25-35
Q 25.37 What are the primary sources of federal health care regulation that may impact the acquisition of a physician practice?	25-35
Q 25.38 What Medicare regulations may be implicated?	25-35
Q 25.39 What are Provider Transaction Access Numbers and National Provider Identification Numbers?	25-37
Q 25.40 What approvals are required in order for physicians (or their employers) to provide, and bill for, services to Medicare beneficiaries prior to closing?.....	25-37
Q 25.41 How does the buyer acquire the right for the acquired facility or practice group to continue to provide and bill for physician and NPP services to Medicare beneficiaries?	25-38

Chapter 26 Compliance with HIPAA and Other Privacy and Security Laws

Kathleen J. Lester & Melodi M. (Mel) Gates

Sanctions	26-3
Q 26.1 What sanctions enforce compliance with HIPAA?.....	26-3
Overview of HIPAA Coverage	26-4
Q 26.2 What activities does HIPAA cover?	26-4
Q 26.3 What is a “covered entity”?	26-4
Q 26.4 What is a “hybrid entity”?	26-6
Q 26.5 What is a “business associate”?	26-6

HIPAA Compliance	26-8
Q 26.6 What are the core components of HIPAA compliance?	26-8
Q 26.7 Who has responsibility for determining HIPAA compliance?	26-9
Q 26.8 What is an internal HIPAA assessment or audit?.....	26-10
Q 26.9 What documents should a covered entity or business associate establish and maintain?	26-10
Q 26.10 What workforce training programs are required?.....	26-12
Q 26.11 How should the use and disclosure of PHI and ePHI be monitored and tracked?	26-13
Q 26.12 What is the “minimum necessary” standard?.....	26-14
Q 26.13 How should an entity respond to requests from individuals to exercise their rights under HIPAA?.....	26-14
Q 26.14 What administrative, technical, and physical safeguards are required?	26-15
Q 26.15 How should internal and external complaints be handled?	26-16
Impact of the HITECH Act on HIPAA Compliance	26-17
Q 26.16 How does the HITECH Act modify compliance with HIPAA?	26-17
Q 26.17 What are the expanded requirements for business associates?	26-17
Q 26.18 What are the HITECH Act’s changes to the HIPAA limitations on marketing and fundraising communications?	26-18
Q 26.19 What are the changes to the HIPAA “use and disclosure” regulations?	26-19
Q 26.20 What are the breach notification requirements?	26-19
Q 26.21 How will enforcement authority granted to state attorneys general affect HIPAA compliance?.....	26-21
Q 26.22 What is the impact of the new audit requirements?.....	26-22
State Privacy and Security Laws	26-22
Q 26.23 How do state privacy and security laws interact with federal law?	26-22
Evolving Law	26-24
Q 26.24 How does the evolving nature of privacy law affect a due diligence review?	26-24

VOLUME 2

Table of Chapters	v
Table of Contents	ix

Chapter 27 Litigation

Mark P. Goodman & Kristin D. Kiehn

Purposes of Litigation Due Diligence	27-2
Q 27.1 What is litigation due diligence?	27-2
Q 27.2 What is the purpose of litigation due diligence?.....	27-2
Q 27.3 What are the potential consequences of failing to conduct adequate litigation due diligence?	27-3
Basics of Civil Litigation	27-4
Q 27.4 What is civil litigation?	27-4
Q 27.5 What is a class action?.....	27-5
Q 27.6 What is a mass tort action?.....	27-5
Q 27.7 What are the potential consequences of liability in civil litigation?.....	27-5
Q 27.8 What are compensatory damages?	27-6
Q 27.9 What is injunctive relief?	27-6
Q 27.10 What are punitive damages?.....	27-6
Q 27.11 What are treble damages?	27-6
Q 27.12 What is an award of attorneys' fees?	27-6
Common Lawsuits Against Health Care Companies	27-7
Q 27.13 What is patent litigation?	27-7
Q 27.14 What is product liability litigation?.....	27-7
Q 27.15 What is consumer fraud litigation?	27-8
Q 27.16 What is securities litigation?.....	27-8
Q 27.17 What is antitrust litigation?.....	27-9
Q 27.18 What is trademark litigation?.....	27-9
Q 27.19 What is employment litigation?.....	27-10
Q 27.20 What types of contract disputes do health care companies face?	27-10
Q 27.21 What is insurance carrier litigation?.....	27-10

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Regulators and Regulatory Enforcement Actions	27-11
Q 27.22 What is a regulatory enforcement action?	27-11
Q 27.23 What is a criminal enforcement action?	27-11
Q 27.24 What is a civil enforcement action?	27-12
Q 27.25 What are the potential consequences of a regulatory enforcement action?	27-12
Q 27.26 What is the role of the Food and Drug Administration?	27-13
Q 27.27 What is the role of the Department of Justice and U.S. Attorneys' Offices?	27-14
Q 27.28 What is the role of the U.S. Securities and Exchange Commission?	27-15
Q 27.29 What is the role of the Federal Trade Commission?	27-15
Q 27.30 What is the role of the Patent and Trademark Office?	27-15
Q 27.31 What is the role of state attorneys general in enforcing laws against health care companies?	27-15
Q 27.32 What is the role of licensing authorities and accreditation bodies?	27-16
Relevant Statutes	27-17
Q 27.33 What is the Federal Food, Drug, and Cosmetic Act?	27-17
Q 27.34 What is the Prescription Drug Marketing Act?	27-19
Q 27.35 What are securities laws?	27-20
Q 27.36 What are antitrust laws?	27-20
Q 27.37 What is medical malpractice litigation?	27-22
Q 27.38 What is the Stark Law?	27-22
Q 27.39 What are the Foreign Corrupt Practices Act and the UK Bribery Act?	27-23
Q 27.40 What are international trade laws?	27-24
Health Care Fraud	27-24
Q 27.41 What is health care fraud?	27-24
Q 27.42 What are federal health care programs?	27-24
Q 27.43 What is the role of the Office of Inspector General of the U.S. Department of Health and Human Services?	27-25
Q 27.44 What is the Anti-Kickback Statute?	27-26
Q 27.45 What is the False Claims Act?	27-26
Q 27.46 What does it mean to be excluded from federal health care programs?	27-29
Q 27.47 What is a corporate integrity agreement?	27-29
Q 27.48 What is a corporate monitor?	27-30

Table of Contents

Q 27.49	What is the Civil Monetary Penalties Law?	27-30
Q 27.50	What is the Health Care Fraud Statute?.....	27-30
Materiality		27-31
Q 27.51	How is the materiality of a litigation matter assessed?.....	27-31
Q 27.52	Should certain litigation matters be considered presumptively material, regardless of projected financial exposure?.....	27-32
Q 27.53	What is an indemnitor?.....	27-32
Q 27.54	What is successor liability?.....	27-33
Due Diligence Inquiries, Analysis, and Reporting		27-33
Q 27.55	What types of information should be requested?.....	27-33
Q 27.56	Which employees of the target should be interviewed?.....	27-36
Q 27.57	What basic questions should be asked?	27-37
Q 27.58	What is a litigation reserve?.....	27-38
Q 27.59	What is the attorney-client privilege?.....	27-38
Q 27.60	How does the attorney-client privilege become relevant during litigation due diligence?	27-39
Q 27.61	How should the acquiring company respond when a target raises concerns about attorney-client privilege?.....	27-39
Q 27.62	Is it ever appropriate to demand that privileged materials be turned over?	27-39
Q 27.63	How is the value of a potentially material litigation matter assessed?	27-40
Q 27.64	Once the diligence review is complete, how are findings communicated?	27-41
Q 27.65	What is post-closing due diligence?.....	27-42

Chapter 28 Intellectual Property

Scott A. Chambers & Lacy L. Kolo

Due Diligence Overview		28-2
Q 28.1	What are the key intellectual property due diligence issues in health care M&A transactions?	28-2
Patents and Patent Applications		28-3
Q 28.2	What are patents?.....	28-3
Q 28.3	What are the parts of a patent?	28-4
Q 28.4	Do patents have cross-border effects?	28-4

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 28.5	How can one determine which patents, patent applications, and inventions are included in the deal?	28-5
Q 28.6	How is ownership or rights in patents or applications acquired?	28-6
Q 28.7	What does it mean if the list of inventors is not accurate?	28-7
Q 28.8	What is a shop right?	28-8
Q 28.9	How can one confirm that the patent-holding company has full rights to the patents and applications?	28-8
Q 28.10	How can one confirm that the key patents are valid?	28-9
Q 28.11	How can one determine whether the key patents cover the technology?	28-12
Q 28.12	How can one determine if the technology infringes another's patent?	28-13
Q 28.13	How can one determine if patents remain in force?	28-14
Q 28.14	How does FDA exclusivity supplement patent protection for drugs?	28-15
Q 28.15	What is the significance of a listing in the Orange Book?	28-16
Q 28.16	What are continuation, divisional, and continuation-in-part patent applications?	28-17
Q 28.17	How can companies maximize patent terms to extend the life of their product lines?	28-17
Q 28.18	What procedure should a company follow regarding its records of inventions?	28-20
Q 28.19	What is a patent term extension?	28-20
Trademarks	28-21
Q 28.20	What are trademarks?	28-21
Q 28.21	How can a company protect its trademarks and service marks?	28-22
Q 28.22	Why are names important to branded pharmaceuticals?	28-23
Q 28.23	What if the target company has unregistered trademarks?	28-24
Copyrights and Software	28-24
Q 28.24	What are copyrights?	28-24
Q 28.25	What rights permit one to update, improve, or modify any software or copyrighted materials?	28-25
Q 28.26	How should a company protect its copyrights and software?	28-25
Q 28.27	What are the dangers of using open-source software?	28-26
Q 28.28	How does one investigate the protection of software and copyright-eligible intellectual property?	28-27

Table of Contents

Trade Secrets and Know-How	28-27
Q 28.29 What are trade secrets?	28-27
Q 28.30 How do trade secrets complement patents in protecting a company's technology?	28-28
Q 28.31 Can nontechnical matters be protected as trade secrets?	28-28
Q 28.32 What due diligence issues arise if the target has licensed trade secrets?	28-28
Q 28.33 How should trade secrets and know-how be protected from general distribution?	28-29
Other Due Diligence Considerations	28-29
Q 28.34 What if someone has a valid security lien against the acquired intellectual property?	28-29
Q 28.35 How should a company's employment agreements and employee manuals protect intellectual property rights?	28-31
Q 28.36 What due diligence issues may arise with respect to intellectual property litigation?	28-31
Q 28.37 What due diligence issues may arise with respect to proceedings before the Patent and Trademark Office?	28-32
Q 28.38 What are "march-in" rights?	28-32
Q 28.39 Is indemnification typically available for intellectual property infringement?	28-33
Q 28.40 How can due diligence review of freedom-to-operate, clearance, and invalidity opinions be addressed without waiving privilege?	28-34
Q 28.41 What other IP or IP-related issues should be considered during due diligence?	28-34

Chapter 29 Material Contracts

Andrew L. Bab & Dmitriy A. Tartakovskiy

Principal Types of Material Contracts in Health Care Transactions	29-2
Q 29.1 What are the principal types of material contracts that a health care target is likely to have?	29-2
Q 29.1.1 What are the principal types of material contracts that hospitals and other health care service providers are likely to have?	29-3

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 29.1.2	What are the principal types of material contracts that a pharmaceutical or biotechnology company is likely to have?	29-4
Change of Control Provisions		29-5
Q 29.2	What due diligence should be conducted to determine whether the proposed transaction triggers a change-of-control or anti-assignment provision in any of the target's contracts?	29-5
Agreements with Third-Party Payors, Health Care Professionals, and Patient Referral Sources		29-6
Q 29.3	What are the key issues in due diligence review of agreements with third-party payors?	29-6
Q 29.4	What are the key issues in due diligence review of agreements with health care professionals?.....	29-7
Q 29.5	What are the key issues in due diligence review of agreements with patient referral sources?	29-7
Commercial Contracts and Debts		29-8
Q 29.6	How should the target's commercial contracts be evaluated with respect to their economic terms?	29-8
Q 29.7	What other issues may arise in the target's commercial contracts?.....	29-9
Q 29.8	What issues may arise with respect to the target's outstanding indebtedness?	29-10
Agreements Relating to Prior Mergers and Acquisitions		29-10
Q 29.9	What issues may arise with respect to the target's acquisition and disposition agreements?.....	29-10
Joint Venture Agreements		29-11
Q 29.10	What are the key issues when performing due diligence review on joint venture agreements?.....	29-11
Licenses and Other Contracts Involving Intellectual Property		29-13
Q 29.11	What types of agreements relating to intellectual property might a target company have?.....	29-13
Q 29.12	What are the key issues in due diligence review of license-and-collaboration agreements?	29-14

Table of Contents

Q 29.13	What risks are associated with in-licensing of technology rights?	29-15
Q 29.14	What should be the focus when reviewing the target's outbound technology licenses?.....	29-17
Q 29.15	What due diligence concerns arise where the target's research and development agreements address intellectual property ownership and protection?.....	29-17
Q 29.16	What is a material transfer agreement?.....	29-18

Chapter 30 Environmental Considerations

Stuart Hammer

Principal Risks	30-2	
Q 30.1	Why should parties assess environmental risks in health care transactions?	30-2
Q 30.2	What is contamination?.....	30-3
Q 30.3	To what types of environmental claims can a health care company be subject?	30-4
Q 30.4	What types of compliance issues arise in health care transactions?.....	30-5
Principal Environmental Laws Affecting the Health Care Industry	30-5	
Q 30.5	What is the Resource Conservation and Recovery Act?.....	30-5
Q 30.6	What laws regulate medical waste?	30-6
Q 30.7	What is the Clean Air Act?.....	30-7
Q 30.8	What is the Toxic Substances Control Act?	30-8
Q 30.9	What requirements are imposed on storage tanks?	30-8
Q 30.10	What requirements are imposed on dental practices?.....	30-8
Q 30.11	What other environmental statutes may be relevant?	30-9
How Purchasers Can Assess Risk	30-9	
Q 30.12	How can prospective purchasers assess environmental risks?.....	30-9
Q 30.12.1	What documents should the purchaser review?	30-10
Q 30.12.2	Should a purchaser interview the target's personnel?.....	30-10
Q 30.12.3	Should the purchaser commission a Phase I environmental site assessment?	30-11

Contract Provisions	30-12
Q 30.13 What environmental representations and warranties are typically included in purchase agreements in the health care industry?	30-12
Q 30.13.1 What purpose do such representations and warranties serve?	30-13
Q 30.14 Are indemnities used?	30-13

Chapter 31 Employee Benefits

Jonathan F. Lewis & Charles E. Wachsstock

Diligence Overview	31-2
Q 31.1 What are the major elements of diligence relating to executive compensation and employee benefits?	31-2
Q 31.2 What benefits information is typically available with respect to a public target?.....	31-3
Q 31.3 Why do single-employer defined benefit pension plans present significant diligence issues?.....	31-5
Q 31.4 Why do retiree medical benefits present significant diligence issues?	31-6
Issues Involving Senior Management	31-7
Q 31.5 Why do arrangements with senior management present significant diligence issues?.....	31-7
Q 31.6 What are “single-trigger” versus “double-trigger” compensation arrangements?	31-8
Q 31.7 What special rules apply to “golden parachutes”?	31-9
Issues Involving Unions	31-10
Q 31.8 What diligence issues are raised by collective bargaining agreements?	31-10
Q 31.9 What are “multiemployer” pension plans?	31-11
Q 31.10 For multiemployer plans, what is “withdrawal liability”?	31-12
Impact of Health Care Reform	31-13
Q 31.11 Is health care reform significant for due diligence regarding employee benefits?.....	31-13
Q 31.12 What is the significance of section 162(m)(6) of the Internal Revenue Code?.....	31-14

Table of Contents

Carve-out Issues	31-14
Q 31.13 What special considerations apply to carve-out transactions?.....	31-14
Q 31.14 What arrangements may be made for transitional handling of employment benefits?.....	31-15
Q 31.15 What alternatives are available for tax-qualified retirement plans?.....	31-16
Q 31.16 What is “controlled group” liability?.....	31-17
Q 31.17 Under what circumstances might the Pension Benefit Guaranty Corporation intervene in an M&A transaction?	31-18
Downsizing	31-19
Q 31.18 What is the Worker Adjustment and Retraining Notification Act?	31-19
Q 31.19 What antidiscrimination laws may apply in a downsizing?	31-20
Q 31.20 Will terminated employees have a right to continued benefits?.....	31-20
Other Notice Requirements	31-20
Q 31.21 What other employment-related SEC filings might be required?.....	31-20
Q 31.22 What other PBGC filings might be required?	31-21

Chapter 32 Foreign Corrupt Practices Act

Andrew M. Levine & Erich O. Grosz

Scope of the Statute	32-2
Q 32.1 What is the FCPA?.....	32-2
Q 32.2 Who is subject to the FCPA?	32-3
Q 32.3 Who enforces the FCPA?.....	32-3
Q 32.4 What are the potential consequences of violating the FCPA?	32-3
Q 32.5 Do other countries have laws similar to the FCPA?	32-4
Q 32.6 Why is the health care industry particularly susceptible to FCPA risks?.....	32-5

The Antibribery Provisions	32-7
Q 32.7 What types of payments are prohibited by the FCPA's antibribery provisions?	32-7
Q 32.8 Who qualifies as a "foreign official" under the FCPA?	32-7
Q 32.9 What makes a payment "corrupt" for purposes of "obtaining or retaining" business in violation of the FCPA?	32-8
Q 32.10 What type of "knowledge" of a subsidiary's or other affiliate's conduct is required for liability under the antibribery provisions?	32-8
Q 32.11 Can a company be liable for payments made by third parties, such as sales agents, consultants, and distributors?	32-9
Q 32.12 What exceptions are available under the antibribery provisions?	32-9
Q 32.13 What affirmative defenses are available under the antibribery provisions?	32-10
Exposure of Acquiring Companies	32-11
Q 32.14 Is an acquiring company exposed to FCPA liability for the target's violations?	32-11
Q 32.15 What is an acquiring company's potential exposure to liability for the target's antibribery violations?	32-11
Q 32.16 What is an acquiring company's potential exposure to liability for the target's pre-acquisition violations of the accounting provisions?	32-12
Diligence Strategies	32-12
Q 32.17 What are some of the benefits of pre-acquisition FCPA diligence?	32-12
Q 32.18 What steps should a company take as part of pre-acquisition FCPA diligence?	32-13
Q 32.19 What information should be sought during the due diligence process?	32-14
Q 32.20 What types of questions should be asked regarding potential FCPA liability?	32-15
Q 32.21 Can a company ever conduct too much FCPA diligence prior to an acquisition?	32-16
Q 32.22 What if FCPA diligence cannot be completed pre-acquisition?	32-17

Table of Contents

Q 32.23	What post-acquisition steps are advisable where comprehensive FCPA diligence cannot be completed prior to closing?	32-17
Q 32.24	Is requesting a DOJ opinion a viable option?	32-18
Compliance Programs		32-19
Q 32.25	What factors should be considered in assessing whether a target company has a robust FCPA compliance program?	32-19
Q 32.26	What potential FCPA risks should be considered with respect to clinical trials?	32-20
Q 32.27	What potential FCPA risks should be considered with respect to sales and marketing programs?	32-22
Q 32.28	What potential FCPA risks should be considered with respect to government product approvals, product certifications, and other licensing requirements?	32-23
Disclosing Violations to the Government		32-23
Q 32.29	In the M&A context, when is it advisable to disclose an FCPA violation to the government?	32-23
Q 32.30	What considerations weigh in favor of a voluntary disclosure?	32-24
Q 32.31	What considerations militate against a voluntary disclosure?	32-26

Chapter 33 Real Property

Peter J. Irwin

Separate Ownership of Real Estate		33-2
Q 33.1	Are there advantages to having real property held by an entity distinct from the entity conducting health care operations?	33-2
Due Diligence Considerations		33-3
Q 33.2	What kind of real estate diligence is needed as part of a health care M&A transaction?	33-3
Q 33.2.1	What diligence is typically needed for a target's owned properties?	33-3
Q 33.2.2	What diligence is typically needed regarding leased properties?	33-4

Q 33.2.3	What if the property is the subject of a sale-leaseback arrangement?	33-5
Q 33.3	What other issues may arise in real estate diligence?	33-6
Q 33.3.1	How does a prospective acquirer review zoning?	33-6
Q 33.3.2	When should a prospective acquirer review underlying land use issues?	33-6

PART III

TRANSACTION DOCUMENTATION

Chapter 34 Elements of Acquisition Agreements

Andrew L. Bab & Dmitriy A. Tartakovskiy

Principal Elements	34-2	
Q 34.1	What are the principal elements of a health care acquisition agreement?	34-2
Variations	34-3	
Q 34.2	What provisions do parties typically focus on in health care M&A transactions?	34-3

Chapter 35 Representations and Warranties

Andrew L. Bab, Dmitriy A. Tartakovskiy & Jonathan L. Lubin

Purposes and Effects	35-2	
Q 35.1	What is the difference between a representation and a warranty?	35-2
Q 35.2	How can representations and warranties in acquisition agreements be categorized?	35-3
Q 35.3	What purposes do representations and warranties serve in health care acquisition agreements?	35-4
Typical Provisions in Health Care Deals	35-5	
Q 35.4	What industry-specific representations and warranties are typically included in health care acquisition agreements?	35-5

Table of Contents

Q 35.5	What industry-specific representations and warranties are typically included in acquisition agreements involving pharmaceutical or biotechnology companies or medical device manufacturers?	35-6
Q 35.5.1	What representations and warranties relating to legal and regulatory compliance are typical?.....	35-6
Q 35.5.2	What representations and warranties relating to intellectual property are typical?.....	35-9
Q 35.5.3	What representations and warranties relating to material contracts are typical?.....	35-10
Q 35.5.4	What representations and warranties relating to litigation and product liability matters are typical?	35-11
Q 35.6	What additional representations and warranties may be included in purchase agreements relating to product or portfolio acquisitions?.....	35-12
Q 35.7	What industry-specific representations and warranties are typically included in acquisition agreements involving health care providers?.....	35-14
Q 35.7.1	What representations and warranties relating to legal and regulatory compliance are typical?.....	35-15
Q 35.7.2	What representations and warranties relating to the target's participation in Medicare, Medicaid, CHAMPUS, TRICARE, and other federal, state, or local government reimbursement programs are typical?.....	35-17
Q 35.7.3	What representations and warranties relating to the target's accounts receivable and billing practices are typical?.....	35-18
Q 35.7.4	What representations and warranties relating to the target's material contracts are typical?.....	35-19
Q 35.7.5	What representations and warranties relating to the target's licensed personnel and medical staff matters are typical?	35-19
Q 35.7.6	What representations and warranties relating to the target's environmental matters are typical?	35-20
	Limiting the Scope of Representations and Warranties	35-21
Q 35.8	How can parties limit the scope of their representations and warranties in health care acquisition agreements?.....	35-21
Q 35.8.1	What is the role of materiality qualifiers?.....	35-22
Q 35.8.2	What is the role of knowledge qualifiers?	35-23

Chapter 36 Covenants and Deal Protection

*Dmitriy A. Tartakovskiy, Uri Herzberg &
Christopher Anthony*

Pre-Closing Covenants	36-3
Q 36.1 What types of pre-closing covenants related to the transaction process are typically included in health care M&A agreements?.....	36-3
Q 36.2 What is the interim-conduct-of-business covenant?.....	36-4
Q 36.3 What is “gun jumping”?	36-7
Q 36.4 What covenants relating to regulatory approvals and third-party consents may be included in health care acquisition agreements?.....	36-7
Q 36.5 What is a buyer financing covenant?.....	36-9
Q 36.6 What is a financing cooperation covenant?.....	36-9
Q 36.7 What industry-specific covenants are sometimes included in agreements for the acquisition of pharmaceutical, biotechnology, or medical device companies?.....	36-10
Q 36.8 What industry-specific covenants are sometimes included in agreements for the acquisition of a health care service provider?	36-14
Q 36.9 What are the legal consequences of breaching a pre-closing covenant?	36-15
Post-Closing Covenants	36-15
Q 36.10 What types of post-closing covenants are typically included in health care M&A agreements?.....	36-15
Q 36.11 What is a covenant for further assurances?	36-16
Q 36.12 What is a covenant not to compete?	36-17
Q 36.13 What are the remedies for a breach of a post-closing covenant?	36-19
Deal Protection	36-20
Q 36.14 What are deal protection provisions?.....	36-20
Q 36.15 What is a “no-shop” provision?	36-21
Q 36.16 What is a termination fee?.....	36-22
Q 36.17 What is a reverse termination fee?.....	36-23

Chapter 37 Closing Conditions

Andrew L. Bab, Dmitriy A. Tartakovskiy & Chantal Tortoroli

Mutual and Individual Conditions	37-2
Q 37.1 What types of mutual closing conditions typically appear in health care transactions?.....	37-2
Q 37.2 What closing conditions applicable to only one party may appear in health care acquisition agreements?.....	37-3
Conditions Relating to Regulatory Approvals and Third-Party Consents	37-4
Q 37.3 What types of regulatory approvals and third-party consents may be included as closing conditions in health care M&A agreements?	37-4
Q 37.4 What types of antitrust approvals typically constitute closing conditions in health care M&A agreements?.....	37-5
Q 37.5 What other types of regulatory approvals and third-party consents may be included as closing conditions in health care M&A agreements?	37-6
Q 37.6 What are typical points of negotiation with respect to closing conditions relating to regulatory approvals and third-party consents?.....	37-6
Q 37.7 How does the structure of the deal affect the choice of regulatory approvals and third-party consents as closing conditions?.....	37-7
The Bringdown Condition and Related Provisions	37-9
Q 37.8 What is the bringdown condition?	37-9
Q 37.9 Should the bringdown condition require that the representations and warranties be true and correct as of signing as well as of closing?.....	37-9
Q 37.10 Should all of the parties' representations be reaffirmed as of the closing date?	37-10
Q 37.11 What materiality standard should be used?	37-10
Q 37.12 For what representations is a materiality standard considered inappropriate?	37-11
Q 37.13 Is performance of the parties' covenants typically included as a closing condition in health care acquisition agreements?.....	37-12
Q 37.14 What is the purpose of an officer's certificate?.....	37-12

Material Adverse Effect Conditions	37-13
Q 37.15 What is a standalone material adverse effect condition?	37-13
Conditions Specific to the Business or Industry	37-16
Q 37.16 What industry-specific closing conditions may be included in health care acquisition agreements?	37-16

Chapter 38 Documentation for Indemnification

*Andrew L. Bab, Dmitriy A. Tartakovskiy &
Jonathan L. Lubin*

Purposes and Types of Indemnification Provisions in Health Care Acquisition Agreements	38-3
Q 38.1 What purposes do indemnities serve in health care acquisition agreements?	38-3
Q 38.2 What is the interaction of indemnification provisions with purchase price adjustment mechanics?	38-6
Q 38.3 What industry-specific special indemnities may be included in health care acquisition agreements?	38-6
Q 38.3.1 What industry-specific indemnities may be included in acquisition agreements involving pharmaceutical or biotechnology companies or medical device manufacturers?	38-8
Q 38.3.2 What industry-specific indemnities may be included in acquisition agreements involving health care providers?	38-9
Limitations on Indemnification Obligations in Health Care Acquisition Agreements	38-9
Q 38.4 How can parties limit the scope of their indemnification obligations in health care acquisition agreements?	38-9
Q 38.5 What is a cap?	38-10
Q 38.6 What is a basket?	38-10
Q 38.7 What is a materiality read-out?	38-11
Q 38.8 What is a minimum claim threshold?	38-12
Q 38.9 What is a survival period?	38-12
Q 38.10 What is the effect of buyer's knowledge of the breach on indemnification?	38-14
Q 38.11 What is loss mitigation?	38-15

Table of Contents

Q 38.12	Is there an obligation to seek available insurance proceeds?	38-16
Q 38.13	What is the effect of tax benefits on indemnification obligations?	38-16
Security for the Indemnifying Party's Obligations		38-17
Q 38.14	What arrangements may be used to secure indemnification obligations in health care transactions?	38-17
Q 38.15	What is the difference between an escrow and a holdback?	38-17
Transaction Insurance in Health Care Acquisitions		38-18
Q 38.16	What is transaction insurance?	38-18
Q 38.17	Do health care transactions present special problems for this type of insurance?	38-19

Chapter 39 Documentation for License-and-Collaboration Agreements

Kevin A. Rinker & Henry Lebowitz

Licensing and Collaborative Use		39-2
Q 39.1	Which types of intellectual property may be licensed?	39-2
Q 39.2	In what ways may the licensee use the licensed intellectual property?	39-2
Q 39.3	May the licensee sublicense the intellectual property to affiliates or third parties?	39-3
Q 39.4	Which party owns intellectual property developed after the grant date?	39-3
Defense and Enforcement		39-3
Q 39.5	Which party controls the defense or prosecution of infringement claims?	39-3
Q 39.6	What are the potential solutions to a third-party infringement claim?	39-4
Q 39.7	How are recoveries from an enforcement action allocated between the licensor and the licensee?	39-4
Representations, Warranties, and Indemnities		39-5
Q 39.8	How do intellectual property representations and warranties in a license-and-collaboration agreement compare to those in an outright acquisition?	39-5
Q 39.9	What are the key indemnities?	39-5

Confidentiality, Duration, and Wind-Down	39-6
Q 39.10 Should confidentiality obligations be included?	39-6
Q 39.11 What is the typical duration of a license-and-collaboration agreement?	39-7
Q 39.12 What are the typical wind-down arrangements after termination or expiration of the license-and-collaboration agreement?	39-7

Chapter 40 Documentation for Joint Ventures

Sarah A.W. Fitts

Organization of the Joint Venture	40-2
Q 40.1 What legal entities may be used for an equity joint venture?	40-2
Q 40.2 What sorts of contributions do the participants make to an equity joint venture?.....	40-5
Q 40.3 What are the key terms of a joint venture agreement?.....	40-5
Objectives	40-6
Q 40.4 Should the objectives of the joint venture be addressed in the joint venture agreement?.....	40-6
Management and Governance	40-8
Q 40.5 How should management and governance be addressed in the joint venture agreement?.....	40-8
Q 40.6 Should the joint venture have a board of directors?	40-9
Q 40.7 What is the role of officers?	40-9
Q 40.8 What issues arise with respect to decision making by the joint venture participants?.....	40-9
Q 40.9 What if the decision makers do not agree on a course of action?	40-11
Indemnification	40-12
Q 40.10 What kinds of losses can be indemnified?	40-12
Allocation of Income	40-13
Q 40.11 How is income allocated among participants?.....	40-13

Table of Contents

Transfer of Interests	40-14
Q 40.12 Should there be restrictions on transfers of joint venture interests?	40-14
Q 40.12.1 What is a right of first offer?	40-15
Q 40.12.2 What is a right of first refusal?.....	40-15
Q 40.12.3 What is a tag-along right?	40-16
Q 40.12.4 What are drag-along rights?.....	40-16
Q 40.12.5 What are put and call rights?.....	40-17
Q 40.12.6 What are registration rights?	40-17
Q 40.13 What transfer issues arise if a participant’s interests are held by a special-purpose company?	40-17
Termination	40-18
Q 40.14 What are typical circumstances for termination of the joint venture, or the exit of partners?.....	40-18
Q 40.15 What are some important termination issues that should be addressed in the agreement?	40-19

**PART IV
SPECIAL TOPICS**

Chapter 41 Acquisitions of and Other Investments in U.S. Companies by Non-U.S. Buyers

Jeffrey P. Cunard

Statutory Basis	41-2
Q 41.1 What is the source of the U.S. government’s authority to review foreign acquisitions of and other investments in U.S. businesses?	41-2
Jurisdiction of CFIUS	41-3
Q 41.2 What transactions are subject to CFIUS review?.....	41-3
Q 41.2.1 Who is a “foreign person”?.....	41-4
Q 41.2.2 What is a “U.S. business”?	41-4
Q 41.3 What types of control transactions are covered?	41-4
Q 41.3.1 What constitutes control?.....	41-5
Q 41.3.2 What constitutes national security?	41-6
Q 41.3.3 What constitute “critical technologies”?.....	41-7

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 41.3.4	What factors are considered in assessing whether to file with CFIUS?.....	41-7
Q 41.3.5	What health care–related transactions might raise national security concerns?.....	41-8
Q 41.4	What constitutes an “other investment”?.....	41-9
Q 41.4.1	What constitutes “material nonpublic technical information”?.....	41-9
Q 41.4.2	What health care transactions might be “other investments”?.....	41-9
Q 41.5	What real estate transactions are covered?.....	41-10
Q 41.6	What sorts of transactions need to be reviewed by CFIUS?	41-10
Filing a Notice or Declaration		41-11
Q 41.7	Is filing with CFIUS required?	41-11
Q 41.7.1	When is a CFIUS filing mandatory under the pilot program?	41-11
Q 41.7.2	Is a CFIUS filing mandatory for transactions involving foreign-government entities?	41-11
Q 41.8	What is the difference between a Notice and a Declaration?	41-12
Q 41.9	What are the benefits of filing a Notice or Declaration?.....	41-12
Q 41.10	When should the filing be made?	41-12
Q 41.11	What are the contents of the Notice?	41-13
Q 41.12	What are the contents of a Declaration?	41-14
Government Review		41-15
Q 41.13	What is the process prior to the filing of the Notice?.....	41-15
Q 41.13.1	Is there a fee for filing a Notice?	41-15
Q 41.14	What happens after filing of the Notice?	41-15
Q 41.15	What happens during the CFIUS review process?.....	41-17
Q 41.16	What happens after the filing of a Declaration?	41-17
Q 41.17	Are the Notice, Declaration, and CFIUS review process confidential?.....	41-18
Q 41.18	What happens at the end of the Notice or Declaration process?	41-18

Chapter 42 Health Care M&A Transactions in France

Antoine F. Kirry, Antoine d'Ornano & Rosanne Lariven

Principal Considerations in Structuring Health Care M&A Transactions in France	42-5
Q 42.1 What considerations affect the choice between a stock deal and an asset deal?.....	42-5
Stock Deals	42-7
Q 42.2 What are the legal requirements for stock deals involving providers of medical services?.....	42-7
Q 42.3 What are the legal requirements for stock deals involving manufacturers of health products?.....	42-8
Q 42.4 What are the legal requirements for stock deals involving biomedical laboratories?.....	42-9
Asset Deals	42-11
Q 42.5 What are the French law requirements applicable to asset deals generally?.....	42-11
Q 42.6 What are the legal requirements for asset deals involving health care establishments?.....	42-11
Q 42.7 What are the legal requirements for asset deals involving pharmaceutical establishments?.....	42-12
Q 42.8 What are the legal requirements for asset deals involving manufacturers of health products?.....	42-12
Q 42.9 What are the legal requirements for asset deals involving manufacturers of health equipment?.....	42-12
Transfers	42-13
Q 42.10 What are the legal requirements for the transfer of intellectual property rights?.....	42-13
Q 42.11 What are the legal requirements for the transfer of marketing authorizations?.....	42-13
Antitrust, Tax, and Social Security Issues	42-16
Q 42.12 What antitrust notices are required for health care transactions in France?.....	42-16
Q 42.13 What substantive antitrust rules are applicable?.....	42-17
Q 42.14 What are the tax incentives for the development of pharmaceutical or medical devices under French law?.....	42-19
Q 42.15 What pricing considerations are relevant to health care M&A transactions?.....	42-20

Principal Due Diligence Considerations	42-22
Q 42.16 What are the key due diligence considerations in health care M&A transactions in France?	42-22
Q 42.17 What are the key due diligence considerations in transactions involving health institutions?	42-24
Q 42.18 What are the key due diligence considerations in transactions involving developers or manufacturers of health care products?	42-25
Q 42.18.1 What considerations are relevant if the target is a pharmaceutical company?	42-25
Q 42.18.2 What considerations are relevant if the target develops medicinal products?.....	42-26
Q 42.18.3 What considerations are relevant if the target develops or manufactures medical devices?.....	42-28
Q 42.19 What are the operational constraints on health care companies under French law?	42-28
Q 42.20 What are the regulatory constraints on manufacturing health care products in France?	42-30
Q 42.21 What are the regulatory constraints on the distribution and marketing of health care products in France?	42-32
Q 42.21.1 What are the registration and certification requirements?	42-32
Q 42.21.2 What testing is required?	42-33
Q 42.21.3 What are the distribution constraints?	42-34
Q 42.22 What due diligence issues arise with respect to investigations or enforcement actions by governmental agencies involving the target?	42-36
Q 42.23 What are the product liability rules applicable to health care products?	42-37
Q 42.24 What are the medical malpractice liability rules?.....	42-39
Q 42.25 What are the applicable environment law constraints?.....	42-41
Q 42.26 What are the key intellectual property issues relating to medicinal products and medical devices?	42-41
Q 42.27 What are the key personal data issues relating to the health care industry?	42-43
Q 42.28 What are the applicable labor law considerations?.....	42-45
Q 42.29 Are there any issues related to foreign anticorruption programs?.....	42-48

Table of Contents

Transaction Documents	42-49
Q 42.30 What special issues should be addressed in drafting and negotiating transaction documents in health care M&A transactions in France?	42-49
Q 42.31 Is the opinion of the <i>Comité Social et Economique</i> required?	42-50
Q 42.32 How should the transfer of permits be addressed?.....	42-51
Q 42.33 Are any foreign investment approvals required?	42-51
Q 42.34 What are the special documentation requirements in stock deals?.....	42-52
Q 42.35 What are the special documentation requirements in asset deals?	42-52
Q 42.36 What are some typical issues to be addressed in a licensing or collaborative arrangement?.....	42-53

Chapter 43 Health Care M&A Transactions in Germany

Peter Wand

Regulation of Hospitals	43-8
Q 43.1 How is a hospital operated under German law?	43-8
Q 43.2 What are the requirements for patient data protection in German hospitals?	43-9
Q 43.3 How are German hospitals financed?	43-15
Regulation of Medical Care Centers	43-18
Q 43.4 What is a medical care center and how is it connected to the health care sector?	43-18
Q 43.5 How are providers of contractual medical care regulated, and to which extent does that regulation apply to medical care centers?	43-19
Q 43.6 What are further key aspects regarding the regulation of medical care centers?	43-21
Q 43.7 Why are medical care centers of interest to hospitals and external investors?.....	43-23
Regulation of Medicinal Products	43-24
Q 43.8 What regulatory regime governs the development, manufacture, and distribution of medicinal products?.....	43-24
Q 43.9 What is a medicinal product?	43-25

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 43.10	What are the requirements for developing medicinal products in Germany?	43-25
Q 43.11	What are the rules facilitating the development of generic medical products?	43-30
Q 43.12	What are the regulatory requirements for manufacturing medicinal products in Germany?	43-31
Q 43.13	What are the regulatory requirements for marketing medicinal products in Germany?	43-32
Q 43.14	What are the national authorization procedures in Germany?.....	43-33
Q 43.15	What are the European authorization procedures?.....	43-36
Q 43.15.1	What is the centralized procedure in the EU?	43-36
Q 43.15.2	What are the Decentralized Procedure and the Mutual Recognition Procedure in the EU?	43-37
Q 43.16	What are the pricing concerns in connection with the distribution of medicinal products in Germany?	43-38
Q 43.17	What are the basic price regulations for medicinal products in Germany?	43-40
Q 43.18	How are insured persons reimbursed for medicinal product costs?	43-41
Regulation of Medical Devices	43-43
Q 43.19	What is the regulatory regime that governs the development, manufacture, and distribution of medical devices in Germany?	43-43
Q 43.20	What are the requirements for developing and manufacturing medical devices in Germany?.....	43-44
Q 43.21	What are the requirements for distributing medical devices in Germany?.....	43-45
Q 43.22	What are the key provisions of the latest EU Regulation on medical devices?.....	43-46
Q 43.23	What are the pricing concerns in connection with the distribution of medical devices in Germany?	43-48
Q 43.24	What is pharmacovigilance?.....	43-49
Product Liability and Medical Malpractice	43-50
Q 43.25	What special product liability rules apply to medicinal products and medical devices?.....	43-50
Regulation of Health Care Advertising	43-53
Q 43.26	What rules govern advertising in the health care sector?	43-53

Table of Contents

Health Care M&A Issues	43-56
Q 43.27 What are the key considerations in structuring a health care M&A transaction in Germany?	43-56
Stock Transactions	43-57
Q 43.28 What are the key legal considerations in connection with stock transactions?	43-57
Q 43.28.1 What are the considerations for partnerships?	43-58
Q 43.28.2 What are the considerations for limited liability companies?	43-58
Q 43.28.3 What are the considerations for stock corporations and partnerships limited by shares?	43-59
Q 43.29 What are the rights of the target's employees and their representatives in stock transactions?.....	43-61
Q 43.30 What are the tax considerations in stock transactions?.....	43-61
Q 43.31 What are the health care specific issues in stock transactions?.....	43-62
Asset Transactions	43-64
Q 43.32 What are the key legal considerations in connection with asset transactions?.....	43-64
Q 43.33 What are the rules governing the transfer of assets, liabilities, and contracts?	43-64
Q 43.34 What are the rights of the target company's employees and their representatives in asset transactions?.....	43-66
Q 43.35 What are the tax considerations in asset transactions?	43-70
Q 43.36 What are the health care-specific issues in asset transactions?.....	43-71
Q 43.37 What are the key legal considerations in connection with a transfer of intellectual property rights?	43-73
Merger Control, Data Protection, and Other Restrictions	43-74
Q 43.38 What are the key merger control considerations in connection with health care M&A transactions in Germany?	43-74
Q 43.39 What are the key data protection considerations in German M&A transactions?	43-77
Q 43.40 Are there any restrictions on foreign investment?	43-78
Q 43.41 Are there applicable foreign exchange controls or reporting requirements?.....	43-80

Due Diligence	43-81
Q 43.42 What are the key due diligence considerations in health care M&A transactions in Germany?	43-81
Q 43.43 What are the key due diligence considerations in connection with the sale of a hospital business?.....	43-82
Q 43.43.1 What is the importance of determining the legal status of the target hospital?	43-82
Q 43.43.2 What issues arise regarding the financing arrangements of the target hospital?.....	43-82
Q 43.44 What are the key due diligence considerations in connection with the sale of a pharmaceutical or medical devices business?.....	43-83
Q 43.44.1 Why is it important to determine the legal status of the target's products?	43-85
Q 43.44.2 Why is it important to determine whether the target is in possession of necessary marketing authorizations?.....	43-86
Q 43.44.3 What are the potential issues relating to the prescription status and off-label use of the target company's medicinal products?.....	43-87
Q 43.44.4 What are the potential issues relating to pricing and eligibility for health insurance reimbursement?	43-88
Q 43.44.5 What are the potential pharmacovigilance and product liability issues?	43-89
Q 43.44.6 What are the potential issues relating to the protection of intellectual property rights?	43-90

Chapter 44 Health Care M&A Transactions in Russia

Alyona N. Kucher, Anna V. Maximenko & Elena M. Klyuchareva

The Health Care Industry in Russia	44-2
Q 44.1 What are Russia's development goals for the health care industry?.....	44-2
Q 44.2 What recent legislation affects the health care market?	44-3
Q 44.3 What roles does the Russian government play in the health care industry?	44-4

Table of Contents

Structuring Health Care M&A Transactions in Russia	44-7
Q 44.4 How are health care M&A transactions usually structured in Russia?.....	44-7
Q 44.4.1 Why are stock deals more common than asset deals?	44-7
Q 44.4.2 What are typical offshore transactions?	44-8
Q 44.5 What types of companies do health care M&A transactions in Russia primarily involve?.....	44-8
Q 44.6 What types of corporate reorganizations are used in M&A activity in the health care sector?	44-10
Q 44.7 Are there restrictions on foreign ownership of Russian companies operating in the health care market?.....	44-10
Q 44.8 What regulatory approvals are required for M&A transactions in the Russian health care market?	44-12
Q 44.8.1 What transactions require competition clearance?	44-13
Q 44.8.2 What transactions require strategic investment clearance?	44-14
Key Due Diligence Considerations	44-16
Q 44.9 What challenges do buyers face in acquisitions of Russian health care companies?.....	44-16
Q 44.10 What are the key issues in conducting due diligence of a Russian health care company?.....	44-18
Q 44.11 What are the potential issues relating to the seller's title to the shares or assets of the target company?	44-18
Q 44.11.1 What is a void transaction?.....	44-19
Q 44.11.2 What is a voidable transaction?	44-19
Q 44.12 What types of health care activities are subject to licensing?	44-20
Q 44.13 What are the principal industry-specific regulatory requirements?	44-21
Q 44.13.1 What is state registration of pharmaceuticals and medical equipment?.....	44-22
Q 44.13.2 What is state regulation of pricing?	44-22
Q 44.13.3 What are the key regulatory requirements for the manufacture of pharmaceuticals?.....	44-24
Q 44.13.4 What are the requirements for the storage of pharmaceuticals?	44-25
Q 44.13.5 What are the applicable disclosure rules with respect to side effects?	44-25

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 44.13.6	What are the standards and procedures for the provision of medical services?	44-25
Q 44.13.7	What are the rules for accreditation of employees engaged in performing medical or pharmaceutical activities?	44-26
Q 44.13.8	What are the applicable sanitary rules?	44-26
Q 44.13.9	What are the applicable restrictions on advertising?	44-26
Q 44.13.10	What preferences exist for pharmaceuticals originating from the Eurasian Economic Union?	44-27
Q 44.14	How can intellectual property rights to pharmaceuticals and medical equipment be established and protected under Russian law?	44-28
Q 44.15	Are Russian anticorruption requirements consistent with international standards?	44-29
Q 44.16	What are the main labor safety and environmental requirements affecting the Russian health care industry?	44-29
Q 44.17	Can information relating to litigation matters and other disputes involving the target company be obtained from public sources?	44-30
Choice of Law	44-31
Q 44.18	Can the parties choose non-Russian law to govern the deal?	44-31
Arbitration	44-32
Q 44.19	What dispute resolution mechanisms are typically used in health care M&A transactions in Russia?	44-32

Chapter 45 Health Care M&A Transactions in England

Guy Constant

Background	45-2
Q 45.1	What is the role of the public sector?	45-2
Q 45.2	How is the role of the private sector changing?	45-2
Q 45.3	What is the size of the health care market?	45-3
Q 45.4	What factors affect the current health care M&A market?	45-3
Q 45.4.1	What sorts of entities are typically involved in deals?	45-4
Q 45.4.2	How does the public/private distinction affect the market?	45-4

Table of Contents

Q 45.4.3	What are the opportunities in the social care area?.....	45-4
Q 45.4.4	What are the opportunities in the pharmaceuticals area?.....	45-5
Organization of the Public Health Care System in England		45-5
Q 45.5	What is the NHS?	45-5
Q 45.6	What is the “commissioning” of health care services?	45-6
Q 45.7	What is NHS England?	45-6
Q 45.8	What is Monitor or NHS Improvement?.....	45-7
Q 45.9	What is a clinical commissioning group?	45-8
Q 45.10	What is an NHS Trust?	45-8
Q 45.11	What is an NHS Foundation Trust?	45-9
Q 45.12	Can an NHS organization provide privately funded health care?	45-10
Q 45.13	How is the system of health care funded in England?	45-11
Q 45.14	How are prices set for public health care?	45-12
Q 45.15	How are health care services planned and purchased?.....	45-12
Q 45.16	Do elected bodies have any role in the provision of health care?	45-13
Q 45.17	What is the role of local authorities in the planning and provision of health care?	45-13
Q 45.18	How is the provision of health care regulated?	45-14
Q 45.18.1	What is the role of the Care Quality Commission?	45-14
Q 45.18.2	What is the role of Monitor and the NHS Trust Development Authority?	45-15
Q 45.19	How is regulatory oversight managed?.....	45-16
Q 45.20	What happens to failing regulated providers?.....	45-16
Q 45.20.1	What if a private provider fails?	45-17
Q 45.21	How are health care professionals regulated?.....	45-18
Q 45.22	Are there other relevant regulatory authorities?	45-19
Q 45.23	How is the public engaged in the provision of health care in England?	45-20
Q 45.24	What is the role of the Secretary of State for Health in the provision of health care?	45-20
Q 45.25	What is Public Health England?.....	45-20
Q 45.26	What are primary, secondary, and tertiary care, and how are their practitioners organized?	45-21
Q 45.27	Can an NHS Trust (including an FT) or its assets be transferred into private ownership?	45-21

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 45.28	How are medicines licensed for manufacture and use?	45-22
Q 45.28.1	Are there special provisions for herbal medicines?	45-23
Q 45.28.2	Can marketing authorizations be transferred?.....	45-23
Q 45.29	How are medical devices authorized?	45-23
Private Health Care Provision in England		45-24
Q 45.30	What types of activities are currently covered by private company providers?.....	45-24
Q 45.31	How can new private providers enter the English health care market?.....	45-24
Q 45.31.1	What is a startup?	45-25
Q 45.31.2	What is a Public Private Partnership?	45-25
Q 45.31.3	What is a joint venture?.....	45-25
Mergers and Acquisitions Involving Private Health Care Companies		45-26
Q 45.32	How are transactions typically structured?.....	45-26
Q 45.33	How is the purchase price paid?	45-26
Q 45.34	What are the advantages and disadvantages of share purchases?.....	45-27
Q 45.34.1	What protections are available to the buyer in a share purchase?	45-27
Q 45.34.2	What if some assets are to stay with the seller?	45-27
Q 45.35	What are the advantages and disadvantages of asset purchases?	45-28
Q 45.35.1	Are there special considerations for employment contracts?.....	45-28
Q 45.36	Are there alternatives to share and asset purchases?.....	45-29
Q 45.37	Are there restrictions on foreign ownership of companies operating in health care?.....	45-29
Q 45.38	What regulatory approvals are relevant to health care M&A transactions under the Monitor license?.....	45-29
Q 45.38.1	Who is exempt from the requirement of a Monitor license?	45-29
Q 45.39	What competition laws should be considered?	45-30
Q 45.40	What are the tax considerations in share purchase transactions?.....	45-32
Q 45.41	What are the tax considerations in asset purchase transactions?.....	45-33
Q 45.42	Does the choice of law have any impact?	45-33

Table of Contents

Due Diligence	45-34
Q 45.43 Are there particular due diligence issues for share purchases?	45-34
Q 45.44 Are there particular due diligence issues for asset purchases?	45-34
Q 45.45 What issues arise with respect to overtime pay for employees?.....	45-35
Q 45.46 What is the impact of the “duty of candor”?	45-35
Q 45.47 What is the impact of the “any qualified provider” concept?.....	45-35
Q 45.48 What if the seller is subject to product liability claims?.....	45-36
Q 45.48.1 What are the elements of a product liability action?.....	45-36
Q 45.48.2 Who are the potential defendants?.....	45-36
Q 45.48.3 What defenses are available?.....	45-37
Q 45.48.4 What is the limitation period?.....	45-37
Q 45.49 What if the seller is subject to clinical negligence claims?.....	45-37
Q 45.49.1 What are the elements of a tort action for clinical negligence?	45-38
Q 45.49.2 Who are the potential defendants?	45-38
Q 45.49.3 Can a contract action be brought?.....	45-38
Q 45.49.4 What is the limitation period?.....	45-39
Q 45.50 Where can a buyer find published quality or performance data about the target?	45-39
Q 45.51 What data protection considerations apply in health care M&A transactions?	45-39
Q 45.52 Are there particular intellectual property considerations?	45-41
Q 45.53 Does the Bribery Act have any implications in health care transactions?	45-41
Q 45.54 Are there any special requirements to be a director of a health care company?.....	45-42
Q 45.55 What impact will Brexit have on M&A transactions in the health care sector in England?.....	45-42

Chapter 46 Health Care M&A Transactions in Canada

Cheryl Satin & Megan Shaw

Regulatory Environment	46-3
Q 46.1 What is Health Canada?.....	46-3
Q 46.2 What role do the provinces play?	46-4
Q 46.3 What is the role of the Patent Medicine Prices Review Board?	46-5

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 46.4	How is the advertising of health care products regulated?	46-5
Q 46.5	Is there self-regulation in the industry?.....	46-6
Q 46.6	What legislation governs pharmaceutical products, medical devices, and natural health products in Canada?	46-7
Q 46.6.1	What is the scope of the Food and Drugs Act?.....	46-7
Q 46.6.2	What criminal laws are applicable?	46-7
Q 46.6.3	Are there applicable provincial laws as well?.....	46-7
Q 46.6.4	What is the effect of the Patent Act?	46-8
Q 46.6.5	What competition laws apply?	46-8
Structuring the Transaction and Obtaining Regulatory Approvals		46-9
Q 46.7	What considerations affect the choice of a share purchase versus an asset purchase?	46-9
Q 46.8	What is the general process for transferring licenses and approvals for pharmaceutical and medical device products?	46-10
Q 46.9	What notices and approvals do health regulatory authorities require in connection with transactions involving pharmaceutical products?	46-10
Q 46.10	What notices and approvals do health regulatory authorities require in connection with transactions involving medical device products?	46-12
Competition Law		46-14
Q 46.11	What mergers are subject to Canadian competition laws?.....	46-14
Q 46.12	What are the thresholds that trigger a duty to give notice of a merger?.....	46-14
Q 46.12.1	What is the effect of the Canadian thresholds as compared to the lower U.S. thresholds?	46-15
Q 46.13	What substantive test is applied to mergers under Canadian competition/antitrust laws?.....	46-16
Q 46.14	What is the current enforcement policy regarding the health care industry?	46-17
Q 46.15	In what ways does the Canadian Competition Bureau cooperate with agencies in other countries?	46-18
Q 46.16	What are some examples of transactions that have raised competition concerns?	46-19
Investment Canada Act		46-21
Q 46.17	Are there any restrictions on foreign investment in the health care industry in Canada?.....	46-21

Table of Contents

Bulk Sales	46-22
Q 46.18 Is compliance with bulk sales legislation required?	46-22
Some Due Diligence Considerations	46-22
Q 46.19 What are the legal requirements for transferring material contracts?.....	46-22
Q 46.19.1 Should notice be given to the counterparty in any case?	46-23
Q 46.20 What issues should be considered relating to third-party distribution arrangements?	46-24
Q 46.21 What are the anticorruption risk considerations?.....	46-25
Privilege	46-26
Q 46.22 What privileges are recognized in Canadian law?.....	46-26
Q 46.22.1 What is solicitor-client privilege?.....	46-26
Q 46.22.2 What is litigation privilege?	46-27
Q 46.22.3 What is settlement privilege?	46-27
Q 46.22.4 What is common interest privilege?	46-27
Q 46.23 When documents need to be disclosed, what should be done to preserve a potential claim for common interest privilege?.....	46-28
Anti-Spam Laws	46-28
Q 46.24 What restrictions apply to sending commercial electronic messages?.....	46-28
Q 46.25 What are the penalties for violations?	46-29
Q 46.26 What due diligence is appropriate?	46-29
Transaction Documents	46-30
Q 46.27 What documentation is typically required in a share purchase?	46-30
Q 46.28 What documentation is typically required in an asset purchase?	46-31
Q 46.28.1 What is the value of a separate transfer agreement relating to Canadian assets?	46-31
Q 46.29 What is a transition services agreement?	46-32
Product Liability	46-32
Q 46.30 Are class actions used in product liability cases?	46-32
Q 46.31 Are individual actions used in product liability cases?.....	46-33
Q 46.32 What is the basis for a product liability claim?	46-33

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 46.33	Who is potentially liable?	46-34
Q 46.34	What damages may be available?	46-34
Q 46.35	Where can one find public information about claims against the target?	46-35
Anticorruption Laws		46-35
Q 46.36	What are the main Canadian anticorruption statutes?	46-35
Q 46.37	How does the CFPOA address corruption?.....	46-36
Q 46.37.1	Could “foreign public officials” include non-Canadian health care professionals?	46-36
Q 46.37.2	What payments are permitted as exceptions?	46-37
Q 46.37.3	What are the penalties for violations?.....	46-37
Q 46.38	How does the Criminal Code address corruption?	46-38
Q 46.38.1	When is a health care professional a “government official”?	46-38
Q 46.38.2	Do the Criminal Code provisions reach private sector activity?	46-39
Q 46.38.3	What are the penalties for violation of the anticorruption offenses?	46-39
Q 46.39	How does Canadian anticorruption law compare to that of the United States?.....	46-40
Q 46.40	How does Canadian anticorruption law compare to that of the United Kingdom?	46-40
Q 46.41	Can an acquiring company be liable for the target’s anticorruption violations?.....	46-41
Procurement System		46-42
Q 46.42	What is the legal framework applicable to the procurement of health care goods and services in Canada?	46-42
Q 46.43	What information does a purchaser need to know about a target’s eligibility to participate in the Canadian public procurement process?	46-44
Q 46.44	If a target has a bid pending in a binding competitive government procurement, is there anything a purchaser should consider?	46-46

Chapter 47 Health Care M&A Transactions in Japan

Taisuke Igaki & Yoko Kasai

Overview of the Health Care Industry in Japan	47-5
Q 47.1 What is the structure of the health care insurance system in Japan?	47-5
Q 47.2 How are the market prices of drugs determined?.....	47-5
Q 47.3 How are the market prices of medical devices determined?.....	47-6
Structuring Health Care M&A Transactions in Japan	47-6
Q 47.4 How are transactions typically structured?.....	47-6
Q 47.5 What are the primary differences among the structures?	47-7
Q 47.6 What are the differences from a tax perspective?.....	47-8
Q 47.6.1 What is the tax treatment of a stock transfer?	47-8
Q 47.6.2 What is the tax treatment of a business transfer?	47-9
Q 47.6.3 What is the tax treatment of a company split?.....	47-9
Q 47.7 Are there cases where a buyer takes over the tax liabilities of the target?	47-11
Corporate Procedures Required for Each Structure	47-11
Q 47.8 What are the required procedures for stock transfers?	47-11
Q 47.9 What are the required procedures for business transfers?	47-13
Q 47.10 What are the required procedures for company splits?	47-14
Q 47.10.1 What procedures are required under the Companies Act?	47-16
Q 47.10.2 What is a simplified company split?	47-16
Q 47.10.3 How are employee relationships handled in a company split?.....	47-17
Regulatory Framework and Compliance in the Health Care Industry	47-18
<i>Pharmaceuticals and Medical Devices</i>	47-18
Q 47.11 What is the primary law governing the health care industry in Japan?	47-18
Q 47.12 What is a “drug” under the Pharmaceuticals and Medical Devices Act?.....	47-18
Q 47.13 What is a “medical device” under the Pharmaceuticals and Medical Devices Act?.....	47-19
<i>Regulatory Pathways; Licenses and Approvals</i>	47-20
Q 47.14 What are the regulatory pathways for the development of drugs and medical devices?.....	47-20

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Q 47.15	What are the marketing authorizations for drugs?	47-20
Q 47.15.1	What is a marketing authorization holder?	47-21
Q 47.15.2	What is the role of the drug master file system?.....	47-21
Q 47.16	What business licenses are required for manufacturing drugs?	47-21
Q 47.17	What business licenses are required for marketing drugs?.....	47-22
Q 47.18	What are the required regulatory approvals for the marketing of medical devices and in vitro diagnostic drugs?	47-22
Q 47.19	What business licenses are required for manufacturing medical devices and in vitro diagnostic drugs?	47-23
Q 47.20	What business licenses are required for marketing medical devices and in vitro diagnostic drugs?	47-23
Q 47.21	What are the regulatory approvals and business licenses for marketing, manufacturing, and distributing regenerative medicine products?.....	47-24
Q 47.21.1	What marketing authorization is needed for regenerative medicine products?.....	47-24
Q 47.21.2	What marketing business license is needed for regenerative medicine products?.....	47-24
Q 47.21.3	What manufacturing business license is needed for regenerative medicine products?.....	47-24
Q 47.22	What are the procedures for transferring marketing authorizations for drugs and medical devices in connection with health care M&A?	47-25
Q 47.22.1	What are the procedures where a stock transfer is involved?	47-25
Q 47.22.2	What are the procedures where the transaction is a merger, company split, or business transfer?	47-25
Q 47.23	What regulations govern preclinical studies and clinical trials?	47-27
Q 47.24	What post-market safety monitoring is in place for medicinal products?.....	47-27
Q 47.25	What is the relief system for adverse drug reactions in Japan?	47-28
Q 47.26	What are the restrictions on advertising medicinal products?.....	47-28
Q 47.27	What are the restrictions on improper promotional activities for drugs or medical devices?.....	47-29
Q 47.27.1	What is the Fair Competition Code?	47-29

Table of Contents

Q 47.27.2	Is resale price maintenance prohibited?	47-30
Q 47.28	What are the major regulatory compliance issues in the health care industry in Japan?.....	47-30
Other Key Due Diligence Considerations		47-31
Q 47.29	How can intellectual property rights in drugs be protected under Japanese patent law?.....	47-31
Q 47.29.1	What is the term of patent protection?	47-31
Q 47.29.2	Can generic versions of drugs be approved during the patent term?	47-31
Q 47.30	Is there any “data exclusivity” or “market exclusivity” for drugs in Japan?	47-32
Q 47.31	What are the key issues in contract review for health care M&A due diligence?.....	47-32
Q 47.32	What are the merger control regulations in Japan?.....	47-33
Q 47.33	Are there any restrictions on foreign investment?	47-34

Chapter 48 Health Care M&A Transactions in India

Anand Mehta, Agranee Kapoor & Stephanie Nazareth

Background to Health Care in India		48-3
Q 48.1	How is health care regulated in India?.....	48-3
Q 48.2	What is the role of private players in the health care sector?	48-4
Q 48.3	What is the approximate market size of the health care sector in India?	48-5
Structuring an M&A Transaction in India’s Health Care Sector		48-5
Q 48.4	What are the different ways in which a health care deal can be structured in India?	48-5
Q 48.5	What is the legal regime governing an M&A deal in India?.....	48-6
Q 48.6	How are listed companies affected differently in M&A transactions compared to private companies?	48-7
Q 48.7	How does a minority squeeze-out work under Indian laws?	48-7
Q 48.8	How are transactions involving nonresident parties structured and what is the framework governing such transactions?.....	48-9
Q 48.9	What foreign exchange laws govern a health care M&A deal?	48-9

HEALTH CARE MERGERS & ACQUISITIONS AB 2021

Relevant Legal Regimes	48-11
Q 48.10 What are the competition law concerns in India?.....	48-11
Q 48.11 What are the tax implications of a health care M&A transaction?	48-13
Q 48.12 What is the framework of labor laws in India?	48-14
Q 48.13 What are the anti-corruption laws in place in India?.....	48-15
Q 48.14 What are the main concerns about intellectual property in relation to e-health?	48-17
Q 48.14.1 How should patents be handled?.....	48-17
Q 48.14.2 How should nonpatentable technology and know-how be handled?	48-17
Q 48.14.3 How should copyrights be handled?	48-18
Q 48.14.4 How should designs be handled?.....	48-19
Q 48.14.5 How should trademarks be handled?	48-19
Due Diligence Aspects of a Deal	48-20
Q 48.15 What are the due diligence aspects of a health care M&A deal?	48-20
Q 48.16 What are the key considerations that would make a target entity more viable?	48-21
Recent Developments and Trends in the Indian Health Care Sector	48-21
Q 48.17 How does India deal with new and rare diseases?.....	48-21
Q 48.18 How is artificial intelligence contributing to the health care sector?	48-22
Q 48.19 How is teleconsultation improving access to health care?.....	48-23
Q 48.20 How is last-mile delivery improving access to health care?	48-25
Q 48.21 How are medical devices regulated?.....	48-26
Q 48.22 What lies ahead for the health care sector?	48-27
Index	I-1